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Summary 
These recommendations represent the first statement by the Advisory Committee on Immunization Practices (ACIP) on the 
use of a live attenuated vaccine for the prevention of herpes zoster (zoster) (i.e., shingles) and its sequelae, which was licensed 
by the U.S. Food and Drug Administration (FDA) on May 25, 2006. This report summarizes the epidemiology of zoster and 
its sequelae, describes the zoster vaccine, and provides recommendations for its use among adults aged >60 years in the United 
States. 
Zoster is a localized, generally painful cutaneous eruption that occurs most frequently among older adults and 
immunocompromised persons. It is caused by reactivation of latent varicella zoster virus (VZV) decades after initial VZV 
infection is established. Approximately one in three persons will develop zoster during their lifetime, resulting in an estimated 
1 million episodes in the United States annually. A common complication of zoster is postherpetic neuralgia (PHN), a 
chronic, often debilitating pain condition that can last months or even years. The risk for PHN in patients with zoster is 
10%–18%. Another complication of zoster is eye involvement, which occurs in 10%–25% of zoster episodes and can result 
in prolonged or permanent pain, facial scarring, and loss of vision. Approximately 3% of patients with zoster are hospital­
ized; many of these episodes involved persons with one or more immunocompromising conditions. Deaths attributable to zoster 
are uncommon among persons who are not immunocompromised. 
Prompt treatment with the oral antiviral agents acyclovir, valacyclovir, and famciclovir decreases the severity and duration 
of acute pain from zoster. Additional pain control can be achieved in certain patients by supplementing antiviral agents with 
corticosteroids and with analgesics. Established PHN can be managed in certain patients with analgesics, tricyclic antide­
pressants, and other agents. 
Licensed zoster vaccine is a lyophilized preparation of a live, attenuated strain of VZV, the same strain used in the varicella 
vaccines. However, its minimum potency is at least 14-times the potency of single-antigen varicella vaccine. In a large 
clinical trial, zoster vaccine was partially efficacious at preventing zoster. It also was partially efficacious at reducing the 
severity and duration of pain and at preventing PHN among those developing zoster. 
Zoster vaccine is recommended for all persons aged >60 years who have no contraindications, including persons who report 
a previous episode of zoster or who have chronic medical conditions. The vaccine should be offered at the patient’s first clinical 
encounter with his or her health-care provider. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region 
of the arm. A booster dose is not licensed for the vaccine. Zoster vaccination is not indicated to treat acute zoster, to prevent 
persons with acute zoster from developing PHN, or to treat ongoing PHN. Before administration of zoster vaccine, patients do 
not need to be asked about their history of varicella (chickenpox) or to have serologic testing conducted to determine varicella 
immunity. 
Introduction 
The material in this report originated in the National Center for 
Immunization and Respiratory Diseases, Anne Schuchat, MD, Infection with varicella zoster virus (VZV) causes two dis-
Director; and the Division of Viral Diseases, Larry Anderson, MD, tinct clinical conditions. Primary VZV infection causes
Director. varicella (i.e., chickenpox), a contagious rash illness that Corresponding preparer: Rafael Harpaz, MD, National Center for 
Immunization and Respiratory Diseases, CDC, 1600 Clifton Rd., typically occurs among children. A vaccine for preventing 
NE, MS A-47, Atlanta, GA 30333. Telephone: 404-639-6284; Fax: initial VZV infection has been available in the United States 
404-639-8665; E-mail: rzh6@cdc.gov. since 1995, and the Advisory Committee on Immuniza­
tion Practices (ACIP) recommends routine varicella 
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vaccination for all persons aged >12 months who lack evi­
dence of immunity (1–3). Varicella vaccination has dra­
matically reduced chickenpox cases among children (3). 
VZV can reactivate clinically decades after initial infec­
tion to cause herpes zoster (zoster) (i.e., shingles), a local­
ized and generally painful cutaneous eruption that occurs 
most frequently among older adults. Approximately 1 mil­
lion new cases of zoster occur in the United States annu­
ally. Approximately one in three persons in the general 
population will develop zoster during their lifetime. A com­
mon complication of zoster is postherpetic neuralgia 
(PHN), a chronic pain condition that can last months or 
even years. In May 2006, a live, attenuated vaccine for pre­
vention of zoster (ZOSTAVAX®, manufactured by Merck 
& Co., Inc.) was licensed in the United States for use in 
persons aged >60 years. This report provides recommen­
dations for use of zoster vaccine for prevention of zoster 
and its sequelae. 
Methods 
In Spring 2005, Merck & Co., Inc. (Whitehouse Sta­
tion, New Jersey) submitted a Biologics License Applica­
tion to the Food and Drug Administration (FDA) for an 
investigational live, attenuated vaccine for prevention of 
zoster on the basis of a phase 3 clinical trial. These results 
were published in June 2005 (4) and presented at the ACIP 
meeting later that month. In September 2005, ACIP’s 
measles-mumps-rubella and varicella workgroup expanded 
its membership to include experts in adult medicine and 
in zoster and began review of relevant data on zoster and 
the investigational vaccine. Shortly thereafter, this workgroup 
reformed as the ACIP shingles workgroup and, during sub­
sequent months, held 19 conference calls to review and 
discuss scientific evidence related to herpes zoster and zoster 
vaccine, including the epidemiology and natural history of 
zoster and its sequelae, and the safety, immunogenicity, 
efficacy, financing, storage, and handling of the zoster vac­
cine. The workgroup also reviewed several economic analy­
ses on zoster prevention. Workgroup members participated 
in 10 additional conference calls to develop and discuss 
recommendation options for preventing zoster. When sci­
entific evidence was lacking, recommendations incorporated 
expert opinions of the workgroup members. 
Presentations of background materials on zoster and the 
vaccine were made during ACIP meetings in October 2005 
and the three meetings in 2006. Following vaccine licen­
sure on May 25, 2006, recommendation options were pre­
sented to ACIP in June 2006, and final options were 
presented at the October 2006 meeting. During review by 
CDC and external partners, modifications were made to 
the proposed recommendations to update and clarify word­
ing in the document. As new information on the epidemi­
ology and prevention of zoster becomes available, it will be 
reviewed by ACIP and recommendations will be updated 
as needed. 
Background 
Biology of VZV 
VZV is an exclusively human pathogen that infects ap­
proximately 98% of the adult population in the United 
States (5). The primary infection typically occurs during 
childhood and causes varicella. During its viremic phase, 
cell-associated VZV gains access to epidermal cells, caus­
ing the typical varicella rash. The virus then enters sensory 
nerves in mucocutaneous sites and travels through retro­
grade axonal transport to the sensory dorsal root ganglia 
adjacent to the spinal cord where the virus establishes per­
manent latency in neuronal cell bodies (6–7). Latent VZV 
is present in approximately 1%–7% of sensory ganglion 
neurons, with <10 genomic copies per infected cell (8–10). 
Seeding of dorsal root ganglia also might occur during vire­
mia. The magnitude of viremia, the number of skin lesions, 
and the burden of VZV that establishes latency during pri­
mary varicella infection might be linked (11). As with other 
members of the herpesvirus family, VZV is noninfectious 
in its latent form but can reactivate at a later time to form 
intact virions in the involved sensory neurons. These viri­
ons then migrate to the skin through axons, spread from 
cell to cell, and penetrate the epidermis (12). In its full 
clinical expression, zoster causes pain, which is followed by 
a vesicular rash distributed across closely overlapping 
dermatomes of the involved sensory nerve roots. 
The triggers for reactivation of VZV have not been iden­
tified and probably involve multiple factors. However, spe­
cific components of cell-mediated immunity (CMI) have 
an important role in controlling the development of zoster 
by preventing reactivation within the neuron or the full 
clinical expression of reactivated VZV as zoster. The 
effectiveness of these protective components of CMI is well 
maintained in immunocompetent persons during child­
hood and early adulthood. These CMI components are 
believed to be partially or substantially maintained by 
periodic immunologic boosting. “Endogenous boosting” 
might occur in response to subclinical reactivation of 
latent VZV or to development of zoster itself, and “exog­
enous boosting” might occur in response to exposure to 
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VZV circulating in the population as chickenpox (13–19). 
Although virtually all adults are infected with VZV (5), 
specific immunologic parameters have not been identified 
to distinguish who will develop zoster. Anti-VZV antibody 
levels per se are not thought to have a role in zoster preven­
tion (20). Parameters that have been monitored and corre­
late with such protection include anamnestic boost in 
anti-VZV antibodies in vivo in response to VZV-based vac­
cination, and the presence of and boost in memory CD4 T 
cells as measured in vitro by proliferation of peripheral blood 
mononuclear cells (PBMC), by frequency of proliferating 
PBMC, or by frequency of interferon-γ  (IFN-γ ) releasing 
PBMC, all in response to VZV-antigens (21,22). These 
latter two parameters are generally assessed using a responder 
cell frequency (RCF) assay and an IFN-γ enzyme-linked 
immunosorbent spot-forming cell (ELISPOT) assay, respec­
tively (22). VZV-specific class I-restricted and unrestricted 
cytotoxicities also have been monitored using target cell 
lysis (23). Although CMI is necessary for the control of 
zoster, other nonimmunologic factors also might be involved 
(24). 
Clinical Features of Zoster and PHN 
The clinical course of acute zoster is variable. It is usually 
less severe in children and younger adults. Typically, zoster 
begins with a prodrome. Headache, photophobia, and 
malaise might occur, with fever being less common. 
Abnormal skin sensations and pain of varying severity are 
the most common symptoms. These symptoms can pre­
cede the zoster rash by days to weeks (25) and rarely might 
be the only clinical manifestation of VZV reactivation 
(termed zoster sine herpete) (7). Pain is described as ach­
ing, burning, stabbing, or shock-like. Altered sensitivity to 
touch, pain provoked by trivial stimuli, and unbearable 
itching are all frequently reported. 
Zoster rash is typically unilateral and does not cross the 
mid-line, erupting in one or two adjacent dermatomes. The 
frequency of zoster occurrence in different dermatomes has 
been evaluated in certain studies. In general, thoracic, cer­
vical, and ophthalmic involvement are most common 
(Figure 1) (26–28). Small numbers of lesions can occur 
outside the primary or adjacent dermatome. The rash is 
initially erythematous and maculopapular but progresses 
to form coalescing clusters of clear vesicles containing high 
concentrations of VZV (Figure 1). The vesicles form over 
several days and then evolve through pustular, ulcer, and 
crust stages. The rash usually lasts 7–10 days, with com­
plete healing within 2-4 weeks. However, pigmentation 
changes and scarring might be permanent. Streptococcal 
FIGURE 1.Thoracic distribution of zoster (A), and zoster rash 
with coalescing clusters of clear vesicles (B) 
or staphylococcal superinfections might complicate zoster 
rash (29). 
A common and potentially debilitating consequence of 
zoster is PHN, a persistent pain after resolution of the rash. 
Pathologic observations thought to distinguish PHN from 
uncomplicated zoster include axonal and cell body degen­
eration, atrophy of the spinal cord dorsal horn, scarring of 
the dorsal root ganglion, and loss of epidermal innervation 
of the affected area. Certain experts believe this neuronal 
damage might be caused by ongoing viral replication 
(30,31). In addition, consensus is lacking regarding crite­
ria needed to distinguish the quality, duration, or underly­
ing pathophysiology of pain occurring with zoster versus 
PHN. Therefore, the duration of pain used to define PHN 
has been inconsistent, ranging from any duration after reso­
lution of the rash to periods from >30 days to >6 months 
after rash onset. 
Regardless of definition, the pain of PHN can last for 
weeks or months and occasionally persists for many years. 
The nature of PHN pain varies from mild to excruciating 
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in severity, constant, intermittent, or triggered by trivial 
stimuli. Approximately half of patients with zoster or PHN 
describe their pain as “horrible” or “excruciating”, ranging 
in duration from a few minutes to constant on a daily or 
almost daily basis (32). The pain can disrupt sleep, mood, 
work, and activities of daily living, adversely impacting the 
quality of life and leading to social withdrawal and depres­
sion (Table 1) (31–33). Anecdotes of suicide among 
patients suffering from PHN have been reported (34; Peter 
Richards, MD, personal communication, 2007). Among 
persons experiencing zoster, predictors of PHN include the 
occurrence and severity of pain both before and after onset 
of the rash, the extent of the rash, trigeminal or ophthalmic 
distribution (35,36), and the occurrence of viremia (37). 
In addition to PHN, zoster is associated with a variety of 
other complication. Among persons with zoster, 10%–25% 
have eye involvement, called herpes zoster ophthalmicus 
(HZO) (38,39) (Figure 2). HZO can occur when reactiva­
tion involves the nasociliary branch of the trigeminal nerve, 
sometimes preceded by the presence of zoster vesicles on 
the nose (Hutchinson sign). Keratitis occurs in approxi­
mately two thirds of patients with HZO (40), often caus­
ing corneal ulceration. Other complications include 
conjunctivitis, uveitis, episcleritis and scleritis, retinitis, 
choroiditis, optic neuritis, lid retraction, ptosis, and glau­
coma. Extraocular muscle palsies also occur. Prolonged or 
permanent sequelae of HZO include pain, facial scarring, 
and loss of vision (41). 
An uncommon complication of zoster is Ramsay Hunt 
syndrome, a peripheral facial nerve palsy accompanied by 
zoster vesicles on the ear, hard palate, or tongue (42). The 
pathophysiology of this complication involves reactivation 
of VZV in the geniculate ganglion of the facial nerve. 
Additional signs and symptoms of Ramsey Hunt syndrome 
can include pain, vertigo, hearing loss, sensitivity to sound, 
tinnitus, and loss of taste. Many patients do not recover 
TABLE 1. Impact of acute herpes zoster and postherpetic 
neuralgia on quality of life 
Life factor	 Impact 
Physical	 Chronic fatigue 
Anorexia and weight loss 
Physical inactivity 
Insomnia 
Psychological	 Anxiety 
Difficulty concentrating 
Depression, suicidal ideation 
Social Fewer social gatherings 
Changes in social role 
Functional Interferes with activities of daily living (e.g., dressing, 
bathing, eating, travel, cooking, and shopping) 
FIGURE 2. Case of herpes zoster ophthalmicus 
Photo/MN Oxman, University of California, San Diego 
completely (42). Idiopathic facial palsy (Bell’s palsy) might 
be caused by inapparent VZV reactivation (42,43). 
Occasionally, zoster can cause motor weakness in 
noncranial nerve distributions, called zoster paresis (44,45). 
The mechanism has not been determined. The weakness 
develops abruptly within 2–3 weeks after onset of the rash 
and can involve upper or lower extremities. Diaphragmatic 
paralysis also has been described. The prognosis of zoster 
paresis is good (46). Zoster also can result in autonomic 
dysfunction, causing urinary retention and colon pseudo-
obstruction. 
Rarely, patients will experience acute focal neurologic 
deficits weeks to months after resolution of the zoster rash, 
involving the trigeminal distribution contralateral to the 
initial rash. This ischemic stroke syndrome, termed 
granulomatous angiitis, is believed to be caused by direct 
extension of VZV from the trigeminal ganglion to the 
internal carotid artery or its branches, resulting in inflam­
mation (30). Mortality from this syndrome is substantial. 
Other rare neurologic complications of zoster include 
myelitis, aseptic meningitis, and meningoencephalitis. The 
prognosis for these conditions is good, although encepha­
lomyelitis can be life threatening. Guillain-Barré syndrome 
also has been reported in association with zoster (47). 
In immunocompromised persons, zoster initially might 
present typically. However, the rash tends to be more 
severe and its duration prolonged (48,49). One specific 
risk for persons with some immunosuppressive conditions 
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is dissemination of the zoster rash. True cutaneous dissemi­
nation generally occurs only among immunocompromised 
patients, occurring in up to 37% of zoster cases in the 
absence of antiviral treatment (49–54). Dissemination usu­
ally begins with a dermatomal rash; however, the rash some­
times begins with no primary dermatomal involvement (54). 
Cutaneous dissemination is not life-threatening; however, 
it is a marker for VZV viremia that can seed the lungs, 
liver, gut, and brain and cause pneumonia, hepatitis, 
encephalitis, and disseminated intravascular coagulopathy 
in 10%–50% of episodes. Visceral dissemination with no 
skin involvement can occur in profoundly 
immunocompromised persons. Even with antiviral treat­
ment, the case fatality rate from visceral dissemination is 
5%–15%, with most deaths attributable to pneumonia 
(49,54,55). 
The risk for neurologic zoster complications is generally 
increased in immunocompromised persons. These compli­
cations, which can be aggressive and even fatal, include 
myelitis, chronic encephalitis, ventriculitis, meningoen­
cephalitis, and cranial palsies (30). However, the risk for 
PHN is not appreciably increased among immuno­
compromised persons who develop zoster (30). 
Compared with other immunocompromised persons, the 
clinical features of zoster are less severe and visceral dis­
semination less common among persons infected with 
human immunodeficiency virus (HIV) (56,57). Some 
zoster presentations that are unique to persons infected with 
HIV include atypical skin eruptions (58,59) and an 
aggressive variant of acute retinal necrosis that generally 
results in blindness (60). Alveolar bone necrosis and tooth 
exfoliation also have been reported (61). 
Diagnosis 
Zoster diagnosis might not be possible in the absence of 
rash (e.g., before rash or in cases of zoster sine herpete). 
Patients with localized pain or altered skin sensations might 
undergo evaluation for kidney stones, gallstones, or coro­
nary artery disease until the zoster rash appears and the 
correct diagnosis is made (62). In its classical manifestation, 
the signs and symptoms of zoster are usually distinctive 
enough to make an accurate clinical diagnosis once the rash 
has appeared (63). Occasionally, zoster might be confused 
with impetigo, contact dermatitis, folliculitis, scabies, 
insect bites, papular urticaria, candidal infection, dermati­
tis herpetiformis, or drug eruptions. More frequently, zoster 
is confused with the rash of herpes simplex virus (HSV), 
including eczema herpeticum (4,31,64–66). The accuracy 
of diagnosis is lower for children and younger adults in 
whom zoster incidence is lower and its symptoms less 
often classic. 
In some cases, particularly in immunosuppressed per­
sons, the location of rash appearance might be atypical, or 
a neurologic complication might occur well after resolu­
tion of the rash. In these instances, laboratory testing might 
clarify the diagnosis (67–71). Tzanck smears are inexpen­
sive and can be used at the bedside to detect multinucle­
ated giant cells in lesion specimens, but they do not 
distinguish between infections with VZV and HSV. VZV 
obtained from lesions can be identified using tissue cul­
ture, but this can take several days and false negative 
results occur because viable virus is difficult to recover from 
cutaneous lesions. Direct fluorescent antibody (DFA) stain­
ing of VZV-infected cells in a scraping of cells from the 
base of the lesion is rapid and sensitive. DFA and other 
antigen-detection methods also can be used on biopsy 
material, and eosinophilic nuclear inclusions (Cowdry type 
A) are observed on histopathology. Polymerase chain reac­
tion (PCR) techniques performed in an experienced labo­
ratory also can be used to detect VZV DNA rapidly and 
sensitively in properly-collected lesion material, although 
VZV PCR testing is not available in all settings. A modifi­
cation of PCR diagnostic techniques has been used at a few 
laboratories to distinguish wild-type VZV from the Oka/ 
Merck strain used in the licensed varicella and zoster 
vaccines. 
In immunocompromised persons, even when VZV is 
detected by laboratory methods in lesion specimens, dis­
tinguishing chickenpox from disseminated zoster might not 
be possible by physical examination (72) or serologically 
(73–75). In these instances, a history of VZV exposure, a 
history that the rash began with a dermatomal pattern, 
and results of VZV antibody testing at or before the time 
of rash onset might help guide the diagnosis. 
Zoster Transmission 
Zoster lesions contain high concentrations of VZV that 
can be spread, presumably by the airborne route (76,77), 
and cause primary varicella in exposed susceptible persons 
(77,78–83). Localized zoster is only contagious after the 
rash erupts and until the lesions crust. Zoster is less conta­
gious than varicella (78). In one study of VZV transmis­
sion from zoster, varicella occurred among 15.5% of 
susceptible household contacts (78). In contrast, following 
household exposure to varicella, a more recent study dem­
onstrated VZV transmission among 71.5% of susceptible 
contacts (84). In hospital settings, transmission has been 
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documented between patients or from patients to health-
care personnel, but transmission from health-care person­
nel to patients has not been documented. Persons with 
localized zoster are less likely to transmit VZV to suscep­
tible persons in household or occupational settings if their 
lesions are covered (85). 
Epidemiology of Zoster and 
Complications 
Risk Factors 
Infection with VZV 
Wild-type VZV. Because zoster reflects reactivation of 
latent VZV, the primary risk factor and a necessary precon­
dition for zoster is previous VZV infection. Approximately 
99.5% of the U.S. population aged >40 years has serologic 
evidence of previous infection, including all evaluated sub­
groups; therefore, all older adults are at risk for zoster (5), 
although many cannot recall a history of varicella (86–90). 
Varicella vaccine is effective at preventing initial wild-type 
VZV infection in persons not previously infected. Any wild-
type VZV infections prevented cannot reactivate as zoster. 
The age at the time of initial VZV infection influences 
the age at which zoster occurs. Persons acquiring an intrau­
terine or early childhood infection with VZV are at 
increased risk for pediatric zoster (91–93). When VZV 
infections occur before age 2 months, the risk for zoster 
occurring by the age of 12 years is increased >35-fold com­
pared with the risk for VZV infections occurring after 
infancy (92). Other case series suggest that the risk for 
pediatric zoster also might be increased in children who 
experienced varicella at older ages (94). Conversely, the risk 
for zoster might be diminished in persons born in coun­
tries (95) or living in communities (96) where varicella 
infection tends to occur at later ages. These observations 
suggest that changes in the epidemiology of varicella caused 
by varicella vaccination or by other factors can alter the 
epidemiology of zoster, particularly pediatric zoster. 
Oka/Merck Strain VZV. Among vaccine recipients, the 
attenuated Oka/Merck strain of VZV included in varicella 
vaccine also can establish a latent infection and clinically 
reactivate as zoster (97). Zoster caused by Oka/Merck strain 
VZV cannot be distinguished on clinical grounds from 
zoster caused by wild-type VZV. The risk for zoster caused 
specifically by Oka/Merck strain VZV is unknown because 
recipients of varicella vaccine might have already been 
infected with wild-type VZV or might have become 
infected with wild-type VZV following vaccination (i.e., 
due to vaccine failure) that could also reactivate. Therefore, 
the rate of all episodes of zoster among varicella vaccine 
recipients define the upper bound for the risk of the subset 
of episodes caused by Oka/Merck strain VZV. The risk for 
zoster in immunocompromised children was approximately 
65% less for those who had received the varicella vaccine 
compared with those with previous wild-type varicella in­
fection (98,99). In immunocompetent children, the risk 
also appears to be reduced among 1-dose vaccine recipi­
ents compared with children with a history of wild-type 
varicella, although longer follow up is needed (99–101). 
The risk for zoster in immunocompetent children follow­
ing 2 doses of varicella vaccine has not been studied. Col­
lectively these studies suggest that the risk for Oka/Merck 
strain zoster following varicella vaccination is no higher, 
and likely considerably lower, than that following wild-
type varicella infection, even though the acquisition of the 
Oka/Merck VZV through vaccination generally occurs at a 
young age (i.e., varicella vaccination is recommended for 
children aged >12 months [1–3]), which might be a risk 
factor for pediatric zoster. As varicella vaccine recipients age, 
the risk for and manifestation of Oka/Merck strain zoster 
in older persons at greater risk for zoster complications can 
be evaluated. 
Age 
Influence on zoster. Age is the most important risk fac­
tor for development of zoster (Figure 3). Virtually all stud­
ies conducted in numerous settings and with various study 
designs have indicated an association between age and 
increasing zoster incidence, extending to the oldest cohorts 
(4,62,95,102–104). One study indicated that zoster inci­
dence increased with age by a factor of >10, from 0.74 per 
1000 person years in children aged <10 years to 10.1 per 
1000 person years in persons aged 80–89 years, with much 
of the increase beginning at age 50–60 years (13). Approxi­
mately 50% of persons who live to age 85 years will have 
experienced zoster (105,106). 
The important role of age as a risk factor for zoster is 
presumably related to a loss of components of VZV-
specific CMI response because of aging (i.e., immune 
senescence) possibly combined with waning immunity that 
might occur over time following initial varicella infection. 
Loss of specific immunity allows VZV to complete the pro­
cess of reactivation and spread to the epidermis to produce 
the fully expressed clinical illness (12). Although precise 
correlates of protection against zoster have not been identi­
fied, certain CMI responses to VZV antigen decline with 
age (21,22,107,108). 
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FIGURE 3. Rate* of zoster and postherpetic neuralgia (PHN)†, 
by age — United States 
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†Defined as >30 days of pain. 
Influence on PHN. Among persons experiencing zoster, 
the primary risk factor for the development of PHN is age. 
Several studies have indicated that the risk for PHN among 
persons with zoster increases with age, particularly for per­
sons aged >50 years (13,35,62,109,110) (Figure 3). In one 
study, the risk for experiencing at least 2 months of pain 
from PHN increased 27.4-fold among patients aged >50 
years compared with those aged <50 years (109). Approxi­
mately 80%-85% of PHN occurs in zoster patients aged 
>50 years (62). 
Sex 
Results from a large, randomized, controlled vaccine trial 
in the United States (4) indicated that the incidence of 
confirmed zoster cases in a cohort of immunocompetent 
persons aged >60 years was 11% higher among the women 
(11.8 versus 10.7 cases per 1000 person years in women 
and men, respectively). A prospective cohort study in the 
Netherlands documented 38% more cases among women 
than men (odds ratio = 1.38 [95% confidence interval [CI] 
= 1.22–1.56) after controlling for age and other zoster risk 
factors (111). Other studies (13,102–104,112) using a 
variety of methods also demonstrated an age-standardized 
excess of zoster among women. However, some researchers 
did not find a difference by sex (36,38,105,113–115). 
Women with zoster might also be at increased age-specific 
risk for developing PHN compared with men (35,62). 
Race 
Certain studies have suggested racial differences in the 
risk for zoster. In North Carolina, reported lifetime zoster 
occurrences and reported incidence were lower in blacks 
by 65% and 75%, respectively, compared with whites 
after controlling for relevant confounders (115,116). A 
study in the United Kingdom indicated that zoster risk in 
patients was 54% lower among blacks after adjusting for 
age, sex, country of birth, or household childhood contacts 
(95). The reasons for these racial differences are unknown. 
Geographic or Seasonal Variation 
Most studies have not documented a seasonal pattern to 
zoster incidence (13,38,92,95,105,117). Certain studies 
have reported summer seasonality, particularly for exposed 
skin sites. This pattern might be related to ultraviolet irra­
diation that peaks during summer months and might serve 
as a trigger for zoster (28,118,119). No studies exist 
regarding variation in zoster incidence by latitude. Urban/ 
rural status does not appear to be a risk factor for zoster 
(95). 
Altered Immunocompetence 
Unlike other vaccine-preventable diseases, zoster epide­
miology is not directly related to exposure but to the biol­
ogy underlying the virus-host relation that allows reactivation 
of latent VZV. Because CMI plays a key role in controlling 
both development of zoster and the features of its clinical 
expression, deficiencies in CMI, regardless of their etiol­
ogy, are risk factors for both zoster and its severe manifesta­
tions. Although the magnitude of zoster risk can be 
extremely high among immunocompromised persons, the 
overall population attributable risk is modest because 
immunosuppression is uncommon (62,103,114). 
The incidence of zoster is increased substantially in per­
sons with hematologic malignancies and solid tumors (120). 
Rates are highest among children with these conditions. 
The magnitude of risk depends on both the nature of the 
underlying cancer and the type of treatment (121). 
Although the incidence of zoster in patients with solid 
tumors is <5%, this rate is many-fold higher than that in 
unaffected age-matched persons (120). Patients with 
Hodgkin’s disease are at particularly high risk for zoster, 
with cumulative risks during the illness and its treatment 
as high as 27.3% (51,53,120,122–127). 
Zoster is common following hematopoietic stem cell 
transplantation (HSCT); rates are 13%–55% during the 
first year (54,128,129). Rates are increased following solid 
organ transplants (renal, cardiac, liver, and lung) (5%– 
17%). Incidence is highest during the months immedi­
ately following the procedure, and the majority of zoster 
cases occur within a year of transplantation (130–132). 
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The risk for zoster and its recurrence is elevated in per­
sons infected with HIV. Zoster rates of 29.4–51.5 per 1000 
person years have been reported among HIV-infected 
adults, reflecting 12- to 17-fold increase compared with 
HIV-negative persons (56,133–136). For HIV-infected 
children, the risk is even higher (467 per 1000 person years), 
especially among children who acquire VZV infection when 
they are profoundly immunosuppressed (137). Most studies 
have documented increasing zoster risk as CD4+ 
T-lymphocyte counts decline, but the risk is increased nine­
fold even among HIV-infected women with CD4+ 
T-lymphocyte counts >750/µL compared with HIV-
negative controls (135). However, the risk might decline at 
CD4+ T-cell counts <50 cells/µL (136). Persons infected 
with HIV also are at increased risk for recurrences of zoster. 
Other Co-morbidities 
The risk for zoster appears to be elevated in persons with 
inflammatory diseases; however, for most of these condi­
tions, data are insufficient to determine how much of the 
risk is attributable to the underlying disease versus its treat­
ment. Zoster has been associated with systemic lupus 
erythematosus (SLE), with rates of 15–91 per 1000 per­
son years (138–143). The risk for zoster also is increased 
among persons with rheumatoid arthritis (adjusted hazard 
ratio = 1.9 [95% CI = 1.8–2.0]), with an incidence of 
approximately 10 cases of per 1000 person years reported 
(144,145). Patients with Wegener’s granulomatosis have a 
reported incidence of 45 zoster cases per 1000 person years 
(146), and recurrences in these patients are common. In 
one study, Crohn’s disease and ulcerative colitis were both 
associated with a significantly increased risk for zoster 
(incident rate ratios = 1.6 and 1.2, respectively). The 
increase was, in part, caused by use of immunosuppressive 
medications (147). For all these conditions, zoster is gen­
erally not life-threatening, although cutaneous dissemina­
tion is more common, and deaths have been reported in 
such patients (138,141,142). 
Certain studies have evaluated the risk for zoster in per­
sons with other noninflammatory co-morbid conditions, 
although findings have not been consistent. Two studies 
have documented an association between zoster and diabe­
tes mellitus (148,149). However, this association was not 
indicated in two other studies (150,151). Another study 
documented an increased risk for zoster in persons who 
subsequently had multiple sclerosis diagnosed (152). 
Exposure to VZV/External Boosting 
VZV can be transmitted from zoster lesions to cause pri­
mary varicella in susceptible persons. Although some 
experts have suggested that zoster can be caused directly 
by exposure to VZV from varicella or from other cases of 
zoster (72,153,154), in general, zoster is not associated with 
epidemics of varicella. In addition, zoster does not have a 
seasonal pattern to suggest it is spread directly from vari­
cella (13,28,38,92,105,117). Theoretically, reactivation of 
latent VZV might be triggered by exposure to exogenous 
VZV (123,153); however, no evidence suggests that such 
episodes occur more frequently than would be expected to 
occur by chance. 
Conversely, exposure to varicella might reduce the risk 
for zoster (13). Protection might be partially maintained 
by exposure to varicella circulating in the population and 
the resulting exogenous boosting of VZV-specific immu­
nity (15,117,155). An analysis of surveillance data from 
the United Kingdom indicated an inverse relation between 
annual varicella incidence in children aged <5 years and 
zoster incidence in adults aged 15–44 years (117). A case-
control study in the United Kingdom (15) documented a 
graded reduction in zoster risk as a function of number of 
varicella contacts over a 10-year period. Multivariate analy­
sis suggested a 74% reduction in risk for zoster among per­
sons with three to four varicella exposures compared with 
those with no exposures, with a significant trend suggest­
ing some reduction with fewer than three exposures. Social 
contacts with children (as a proxy for varicella exposure) 
and occupational contact with sick children were protec­
tive (15). A cohort analysis based on data from a sentinel 
physician network in the United Kingdom (155) suggested 
that adults living with children had both increased vari­
cella exposure and a 25% decrease in zoster incidence. The 
analysis estimated that this boosting effect lasted an aver­
age of 20 years (95% CI = 7–41 years). However, persons 
living or interacting with children might have different 
underlying health compared with persons without expo­
sure to children, which might be a confounder in these 
studies. Other evidence that varicella exposure might pro­
tect against zoster includes possible effects household 
exposure to varicella had against subsequent development 
of zoster among children with leukemia (156). Finally, the 
efficacy of the zoster vaccine (4) supports the concept that 
exposure to exogenous VZV can reduce risk for zoster, pre­
sumably by boosting specific immunity against VZV. 
Contrary evidence also exists that varicella exposure does 
not reduce the risk for zoster. Women are at greater risk for 
zoster (13,102,103,110,111) despite the fact that women 
probably have more exposure to young children who expe­
rience varicella. A Japanese study indicated that the risk for 
zoster in children was not diminished by repeated varicella 
exposures (92). 
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Although a sufficient number of varicella exposures could 
reduce the risk for zoster in select populations, it is unclear 
whether such levels of exposure play an epidemiologically 
important role in reducing the risk for zoster among the 
general population of older adults who are at the highest 
risk for the disease, and, if so, how long such effects would 
last in the elderly. 
Other Risk Factors 
As with orofacial and genital flairs of HSV, zoster has been 
anecdotally linked to stress. However, only two rigorous 
evaluations of the role of psychological stress on zoster have 
been conducted. A case-control study documented a sig­
nificant association with number of stressful life events 
within 6 months of reported zoster (p = 0.012) (157). A 
prospective cohort study indicated a nonsignificant asso­
ciation (p = 0.078) between zoster risk and negative life 
events. 
Trauma or surgery could lead to reactivation of VZV in 
the affected dorsal root ganglion and increase the risk for 
zoster rash in that dermatome. Such a development would 
seem to be specific and easily ascertained, and certain 
reports and case series describe such events (158–161). One 
case-control study collected information about recent trauma 
and/or surgery in patients who developed zoster and in 
matched controls. The frequency of trauma in nonzoster 
sites was similar between the two groups, but zoster 
patients were significantly more likely than controls to 
report trauma at the site of their zoster during the month 
before zoster onset (adjusted OR = 12.1 [95% CI = 1.5– 
97.6]; p = 0.002) (24). The basis by which these stimuli 
provoke zoster is unclear, but they suggest that 
nonimmunologic factors can play important roles in the 
pathophysiology of zoster. 
Finally, one study indicated that dietary micronutrient 
intake was protective against zoster. Body mass index did 
not appear to be associated with zoster risk (162). Genetic 
predisposition for zoster also has been reported (163). 
Population Rates of Zoster and PHN 
Zoster 
Zoster is not a reportable condition in the United States; 
therefore, incidence has been inferred from a variety of stud­
ies. Observed rates have varied substantially on the basis of 
methods for case ascertainment, access to health care, and 
case definitions. The age distribution in the population 
being studied also is an important consideration when com­
paring these studies because zoster can vary dramatically 
across study sites. Conclusions cannot be drawn from cross-
study comparisons without adjusting for age or comparing 
age-specific rates directly. Differences in the prevalence of 
immunosuppression or in racial makeup also can influence 
population-wide zoster incidence. In addition, the incidence 
of zoster appears to have been increasing over recent decades, 
even after adjusting for other factors, although this increase 
has not been observed consistently. 
Despite these limitations, certain analyses of zoster inci­
dence in the United States have been conducted. The inci­
dence in all studies ranged from 3.2–4.2 per 1000 
population per year (age-adjusted to the 2000 U.S. popu­
lation) (62,103,104,114,164,165), translating into an 
estimated 1 million cases annually. In all studies, a sub­
stantial increase in zoster incidence occurred with age and 
extended to the oldest strata; for all persons aged >60 years, 
the annual incidence was approximately 10 per 1000 per­
sons (62,103,104,114,164,165), similar to the annual 
incidence of 11.1 per 1000 observed during the zoster vac­
cine trial (4). On the basis of these data, an estimated 32% 
of persons in the United States will experience zoster dur­
ing their lifetime (CDC unpublished data, 2007). 
Certain studies provide evidence of increasing age-
specific zoster incidence in the United States 
(38,62,165,166), although other studies have shown no 
such trend (104). The observed increases cannot be solely 
attributed to changes in the epidemiology of varicella, 
because documentation of increases predated licensure of 
varicella vaccine in the United States in 1995 (38) and 
because age-specific increases over time also are being 
reported in certain international settings, including in the 
absence of varicella vaccination programs (105,167,168). 
Because the basis for this increase remains unclear, predict­
ing whether the age-specific risk for zoster will continue to 
increase in the future is difficult. 
Recurrent Zoster 
Effectively evaluating the risks for recurrent zoster 
(i.e., second or subsequent episodes) in immunocompetent 
persons requires large populations, long-term follow up, 
adequate duration, and laboratory confirmation. Although 
data are limited, certain studies suggest a recurrence rate 
that is comparable to the rate of initial episodes (13,38,114). 
A community-based study of clinician-diagnosed zoster was 
conducted in Olmsted County, Minnesota. The observa­
tional period lasted 6 years. Of 1,669 persons that experi­
enced an episode of zoster during that period, 24 experienced 
a second episode, suggesting a high incidence of zoster 
recurrence and providing no evidence that an episode of 
zoster protects against recurrence (62). Similar observations 
were noted in an older survey-based study (169). In the 
Shingles Prevention Study, two of approximately 20,000 
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vaccine placebo recipients had two episodes of zoster within 
3 years of the initial episode. These cases provide the first 
laboratory-confirmed evidence that zoster can recur in 
immunocompetent persons, even soon after the initial 
episode (4). 
Zoster Hospitalizations and Deaths 
Hospitalizations. Conclusions about hospitalization for 
zoster should be interpreted carefully if they are derived 
from administrative data. Hospital administrative data 
often do not distinguish zoster episodes that were reasons 
for hospitalizations from those episodes that were inciden­
tal to the hospitalization or that occurred during prolonged 
hospital stay. PHN at the time of an unrelated hospitaliza­
tion also might be coded as zoster. In addition, underlying 
immunosuppressive conditions might not be available or 
might not be collected from administrative data. These fac­
tors preclude determination of the portion of hospitaliza­
tions that could be prevented by a live-attenuated vaccine 
that is contraindicated for immunosuppressed persons. 
Given these limitations, crude annual rates of zoster hos­
pitalization have ranged from 2.1 per 100,000 population 
in a Northern California managed care population (170) 
to 4.4 per 100,000 population in England (171). A crude 
rate of 16.1 per 100,000 population was identified in an 
analysis of Connecticut-wide hospitalization data that 
included all zoster episodes, not just primary discharge 
diagnosis (172). 
In a community-based study in Olmsted County, Min­
nesota, approximately 3% of patients with zoster were hos­
pitalized for the illness (62). Although values differ 
substantially, all studies indicate that zoster hospitaliza­
tion rates increase with age (170,172–174). In the Con­
necticut study, zoster hospitalization rates were 
approximately 75-fold greater among persons aged >85 years 
than in persons aged <30 years (172). Although precise 
denominators are not available, risks for hospitalization also 
increased among persons with altered immunocompetence; 
approximately 30% of all persons hospitalized with zoster 
episodes had one or more immunocompromising condi­
tions, primarily malignancies (82%) and HIV infection 
(8%) (62,172). Central nervous system and ophthalmo­
logic complications accounted for most of the reported com­
plications among hospitalized zoster cases (172–174), 
although bacterial superinfection was common in one 
series (175). Another study indicated that 0.5% of patients 
with confirmed zoster were hospitalized before their zoster 
rash developed for prodromal pain syndromes including 
suspected myocardial infarction, severe new-onset headache, 
back pain, and abdominal pain resulting in appendectomy 
(62). 
Deaths. On the basis of clinical experience and in the 
absence of zoster-related deaths in cohort studies, certain 
experts believe that zoster mortality appears to be uncom­
mon, particularly among healthy persons (176). Vital 
records might not distinguish deaths attributed to zoster 
from incidental deaths occurring merely in the presence of 
zoster, and they might not capture information on the im­
munologic status among those deaths. An Australian study 
using administrative data indicated that 1% of patients hos­
pitalized with a primary zoster diagnosis died; the number 
of deaths directly attributable to zoster was not validated 
(174). Certain analyses have indicated that almost all zoster 
deaths occur in the elderly, with a rate >10-fold higher 
among persons aged >65 years (171,173,174). Immuno­
suppression also appears to be a risk factor for zoster mor­
tality. In one study, 52% of patients hospitalized with zoster 
who died had one or more immunocompromising condi­
tion (e.g., malignancies, leukemia, and HIV). In that study, 
the risk for death in persons with immunocompromising 
conditions was 8.7%; the risk in persons without these 
conditions was 3.7% (172). 
PHN 
Drawing conclusions from studies on the risk for PHN is 
difficult because definitions for PHN vary and results are 
influenced by many factors, including the source and age 
of the study population. Among zoster patients treated with 
a placebo in clinical trials of antiviral drugs, approximately 
one third still had pain after 3 months and approximately 
one fourth had pain at 6 months (177,178). However, these 
trials might include a population of patients with more 
severe zoster pain, thereby introducing a detection bias that 
could inflate estimated risks for PHN. In a phase 3 clinical 
trial of zoster vaccine (4), zoster occurred among 642 
placebo recipients; the risk for pain persisting at least 30, 
60, 90, 120 or 180 days among these person was 30.3%, 
17.6%, 12.5%, 8.4%, and 5.1%, respectively. Results from 
the trial might not reflect risks for progression to PHN in 
community settings because ascertainment, diagnosis, and 
antiviral treatment of zoster were standardized and thor­
ough. However, in a community-based study in Olmsted 
County, Minnesota, in which almost all medical events were 
captured, the risk for PHN in patients with zoster was 18%, 
13%, and 10% when defining PHN as at least 30, 60, and 
90 days of pain, respectively (62). 
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Treatment and Nonspecific Management 
of Zoster and PHN 
The treatment of acute zoster, the prevention of PHN 
development among patients with acute zoster, and the 
treatment of patients with current PHN are complex clini­
cal problems with ongoing uncertainties and active research 
(31). Acyclovir, famciclovir, and valacyclovir are approved 
by the FDA for treatment of zoster in immunocompetent 
patients. All three are nucleoside analogs that inhibit rep­
lication of human herpes viruses, including VZV. Clinical 
trials have indicated that these agents, taken orally, reduce 
the duration of viral shedding and lesion formation, 
reduce the time to rash healing, and decrease the severity 
and duration of acute pain from zoster and the risk for pro­
gression to PHN. Because all three antiviral agents are safe 
and well tolerated, many experts recommend that treat­
ment should be considered for all eligible patients with 
zoster, and specifically recommend treatment for persons 
aged >50 years who have moderate or severe pain, moder­
ate or severe rash, or involvement of nontruncal dermatomes 
(31). In clinical trials, treatment has been initiated within 
72 hours of rash onset, a biologically arbitrary time point 
that often is not feasible in clinical practice. The benefits of 
later treatment have not been studied (31). If treatment 
cannot be initiated within 72 hours of rash onset, experts 
recommend that it should be initiated as soon as possible, 
particularly in the presence of new vesicle formation or of 
complications. 
Two clinical trials have assessed the role of corticoster­
oids in combination with acyclovir for treatment of zoster 
and prevention of subsequent PHN (179,180). Patients at 
risk for steroid-related toxicities (e.g., those with diabetes 
mellitus or gastritis) were excluded from the trials. A 3-week 
tapering course of corticosteroids diminished acute zoster 
pain and decreased the time to cutaneous healing, 
cessation of analgesic therapy, and return of uninterrupted 
sleep and normal daily activities. However, no evidence 
indicated that use of corticosteroids prevented development 
of PHN. Theoretically, corticosteroids should be equally 
effective in combination with valacyclovir or famciclovir; 
however, combinations of these agents have not been stud­
ied in clinical trials. No evidence indicates that topical 
antiviral therapy or corticosteroids without systemic 
antiviral therapy have a role in treatment of zoster. 
A variety of approaches have been used with varying 
degrees of success for control of acute zoster pain, includ­
ing acetaminophen, nonsteroidal anti-inflammatory agents, 
tricyclic antidepressants, opiates, anticonvulsants, capsaisin, 
and topical anesthetics (31). In more severe instances of 
pain, referral to a pain specialist, or even hospitalization 
and administration of epidural analgesics, is often consid­
ered. Many of these same modalities are used with varying 
degrees of success for control of chronic PHN pain 
(26,181,182). Elderly persons, who already have reduced 
physiologic reserve and typically take multiple medications 
for pre-existing chronic conditions, might be unable to 
tolerate psychotropic and other medications for manage­
ment of their acute zoster or chronic PHN pain (31,33). 
Patients with uncomplicated zoster should be advised to 
keep the rash clean and dry, to avoid topical antibiotics, 
and, if possible, to keep the rash covered. They should alert 
their physician if the rash worsens or they have fever, which 
could indicate bacterial superinfection (31). 
Prevention of Transmission from Zoster 
Some health-care institutions might exclude personnel 
with zoster from work until their lesions dry and crust (85). 
Persons with localized zoster should avoid contact with 
susceptible persons at high risk for severe varicella in 
household and occupational settings until lesions are crusted. 
Such persons include pregnant women, all premature 
infants born to susceptible mothers, infants born at 
<28 weeks’ gestation or who weigh <1000 g regardless of 
maternal immune status, and immunocompromised per­
sons of all ages (85). Persons with opportunities for contact 
with such high risk-persons in household or occupational 
settings should be informed about how to recognize the 
signs and symptoms of zoster. If a person susceptible to 
varicella infection has close exposure to a persons with zoster, 
postexposure prophylaxis with varicella vaccine or 
VARIZIG™ should be considered (3,85,183). 
Zoster Vaccine 
Vaccine Composition, Dosage, and 
Administration 
The zoster vaccine licensed in the United States 
(ZOSTAVAX®, Merck & Co., Inc.) is a lyophilized prepa­
ration of the Oka/Merck strain of live, attenuated VZV, 
the same strain used in the varicella vaccines (VARIVAX®, 
PROQUAD®). The Oka strain was isolated in Japan (184) 
in the early 1970s from vesicular fluid from a healthy child 
who had varicella; the strain was attenuated through 
sequential propagation in cultures of human embryonic 
lung cells, embryonic guinea-pig cells, and human diploid 
cells (WI-38). Further passage of the virus was performed 
at Merck Research Laboratories in human diploid cell 
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cultures (MRC-5). The cells, virus seeds, virus bulks, and 
bovine serum used in the manufacturing are all tested to 
provide assurance that the final product is free of adventi­
tious agents. 
Zoster vaccine, when reconstituted as directed in the 
package label using the supplied diluent, is a sterile prepa­
ration for subcutaneous administration. Each 0.65-mL dose 
contains a minimum of 19,400 PFU (4.29 log10) of Oka/ 
Merck strain of VZV when reconstituted and stored at room 
temperature for up to 30 minutes. Zoster vaccine is similar 
to VARIVAX®. However, its minimum potency is at least 
14-times the potency of VARIVAX®, which contains a mini­
mum of 1,350 (approximately 3.13 log10) PFU. 
PROQUAD® contains 3.993 log10 PFU, similar in 
potency to ZOSTAVAX®. Each dose of zoster vaccine also 
contains additional VZV antigenic component from non­
viable Oka/Merck VZV. Additional vaccine components in 
each dose include 31.16 mg of sucrose, 15.58 mg of 
hydrolyzed porcine gelatin, 3.99 mg of sodium chloride, 
0.62 mg of monosodium L-glutamate, 0.57 mg of so­
dium phosphate dibasic, 0.10 mg of potassium phosphate 
monobasic, 0.10 mg of potassium chloride; residual com­
ponents of MRC-5 cells including DNA and protein; and 
trace quantities of neomycin and bovine calf serum. The 
product contains no thimerosal or other preservatives. 
Zoster vaccine should be administered as a single 
0.65-mL dose subcutaneously in the deltoid region of the 
upper arm; a booster dose is not licensed for the vaccine. 
The vaccine should not be injected intravascularly or 
intramuscularly and should only be reconstituted and 
injected using a sterile syringe free of preservatives, anti­
septics, and detergents, which can inactivate the vaccine 
virus. 
Storage and Handling 
To maintain potency, lyophilized zoster vaccine must be 
stored frozen at an average temperature of <5°F (<-15°C) 
until it is reconstituted for injection. Any freezer that has a 
separate sealed freezer door and reliably maintains an 
average temperature of <5°F (<-15°C) is acceptable for stor­
ing zoster vaccine. Providers should check the adequacy of 
their freezer by verifying its temperature before obtaining 
vaccine. In general, the freezer compartments of dormitory 
style units are incapable of reliably maintaining tempera­
tures cold enough to store zoster vaccine and are unaccept­
able for storage. For certain refrigerator/freezer models, it is 
necessary to reduce the temperature to the coldest setting 
to maintain zoster vaccine at the correct temperature. How­
ever, this might reduce the temperature in the refrigerator 
compartment and result in freezing of any vaccines or other 
pharmaceutical products being refrigerated. As a result, both 
the refrigerator and freezer temperatures should be moni­
tored and the temperature recorded at least twice a day. 
Any out-of-range temperature readings require immediate 
and documented corrective action. When a freezer is tem­
porarily unavailable (e.g., during transport or equipment 
failure), zoster vaccine should be stored in a suitable con­
tainer (i.e., the original shipping container or a compa­
rable container with a properly fitting lid) with an adequate 
quantity of dry ice (i.e., a minimum of six pound per box) 
so that dry ice would persist in the container if 
unreconstituted vaccine must be transported back to the 
freezer. Dry ice placed in a suitable container will maintain 
a temperature of <5°F (<-15°C). The diluent, which does 
not contain preservative or other antiviral substances that 
could inactivate the vaccine virus, should be stored sepa­
rately, either at room temperature or in the refrigerator. 
The vaccine should be reconstituted according to the 
directions in the package label and only with the diluent 
supplied. Before reconstitution, zoster vaccine should be 
protected from light. Once reconstituted, the vaccine should 
be used immediately to minimize loss of potency. The vac­
cine must be discarded if not used within 30 minutes after 
reconstitution. Information regarding stability under con­
ditions other than those recommended is available from 
the manufacturer at 800-637-2590. 
Efficacy 
The efficacy of zoster vaccine was evaluated in a phase 3 
vaccine trial termed the Shingles Prevention Study, a double-
blind randomized, placebo-controlled trial involving 
38,546 healthy adults aged >60 years who had a history of 
varicella or at least 30 years of residence in the continental 
United States (as a marker of previous infection). Persons 
excluded from the trial included those with a history of 
zoster, with allergies to components of the vaccine, with 
immunocompromising conditions, or with conditions that 
might have interfered with study evaluations (e.g., cogni­
tive impairment, <5 year life expectancy, dermatologic dis­
orders, chronic pain, hearing loss, or lack of mobility). The 
study population ranged in age from 59–99 years (median: 
69.4 years), and comprised 41.0% females, 95.4% white, 
2.1% blacks, 1.3% Hispanics, and 1.2% other or unknown 
race/ethnicity. On enrollment, approximately 90% of the 
participants had at least one underlying chronic medical 
condition. 
Persons were randomized to receive a single subcutane­
ous dose of zoster vaccine or placebo; the mean duration of 
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follow up was 3.1 years. Active case ascertainment was con­
ducted through monthly telephone contact supplemented 
by a close-out interview. Zoster cases were confirmed by 
PCR testing (93%), viral culture (1%), or evaluation by a 
panel of five physicians with expertise in zoster diagnosis 
(6%). Patients with confirmed zoster were followed for at 
least 182 days to assess the outcome of the condition, 
including presence and severity of pain. Approximately 95% 
of persons were followed to completion of the study. Out­
comes evaluated included incidence of zoster, incidence of 
PHN (defined as pain level of three or more [on a numeri­
cal rating scale of 0-10] persisting at least 90 days after 
rash onset), and burden of illness (BOI), measured using a 
mean value of severity-by-duration index for each treatment 
group, thus incorporating the incidence, severity, and 
duration of pain and discomfort from zoster). A total of 
957 confirmed cases of zoster occurred among study par­
ticipants: 315 among vaccine recipients and 642 among 
placebo recipients. The proportion of vaccine and placebo 
recipients that received antiviral treatment within 72 hours 
of rash onset, as clinically indicated, was 64.1% and 65.9%, 
respectively. 
The vaccine reduced the risk for developing zoster by 
51.3% (95% CI = 44.2–57.6; p<0.001 (Table 2) (4). The 
vaccine was 66.5% (95% CI = 47.5–79.2; p<0.001) effi­
cacious for preventing PHN. When the definition of PHN 
was changed from 30 days of pain to 182 days of pain 
following rash onset, vaccine efficacy increased from 58.9% 
to 72.9% (Table 3). Zoster vaccine had an independent 
effect of reducing PHN among patients who developed 
zoster (39% [95% CI = 7%–59%]) (Table 2). The mean 
severity-by-duration of zoster was reduced by 57% 
(p = 0.016) in vaccine recipients who developed PHN. 
Zoster vaccine reduced BOI by 61.1% (95% CI = 51.1– 
69.1; p<0.001) (Table 2). The vaccine reduced the degree 
of interference in activities of daily living (ADLI) caused 
by zoster, in part because of the reduction in zoster itself, 
but also because of a decrease in ADLI among those vac­
cine recipients who did develop zoster (185). No evidence 
indicated that vaccine recipients experiencing zoster were 
protected from other sequelae such as scarring, bacterial 
superinfection, palsies, or ocular or visceral complications 
(186). 
In general, with increasing age at vaccination, the vac­
cine retained efficacy against severity of zoster better than 
against zoster itself. Thus, efficacy for the prevention of 
zoster was highest among persons aged 60–69 years and 
declined with increasing age (Table 2). Declines in efficacy 
of preventing zoster were observed with each 5-year increase 
in age throughout the age range of participants (187). 
However, no significant differences were observed among 
persons aged 60–69 years versus those aged >70 years in 
vaccine efficacy at reducing BOI or PHN, probably 
because the independent effect of reducing PHN among 
patients who developed zoster was greatest among persons 
aged 70–79 years (Table 2). For persons aged >80 years, 
efficacy against zoster was 18% (Table 2), but efficacy against 
PHN (39%) was better retained (186). No significant dif­
ferences by sex were observed in the efficacy of the vaccine 
at reducing BOI, PHN, or zoster (4). No evidence indi­
cated that the vaccine was less efficacious for prevention of 
zoster (vaccine efficacy: 51.6%; 95% CI = 41.4–60.1), 
PHN (vaccine efficacy: 60.9%; 95% CI = 31.3–78.7), or 
for reduction in BOI (vaccine efficacy: 60.1%; 95% CI = 
46.1–70.4) among subjects with functional limitations 
(188). 
TABLE 2. Efficacy of ZOSTAVAX® compared with a placebo, by age group — Shingles Prevention Study* 
ZOSTAVAX® Placebo Efficacy 
% HZ % HZ 
cases cases PHN§ Burden of 
Age group No. HZ PHN with No. HZ PHN with HZ PHN§ with HZ illness (BOI) 
(yrs)† subjects cases cases§  PHN§ subjects cases cases§ PHN§ % (95% CI**) % (95% CI) % (95% CI) % (95% CI) 
60–69 10,370 122 8 6.6 10,356 334 23 6.9 64 (56–71) 65.7 (20.4–86.7) 5 (-107–56) 65.5 (51.5–75.5) 
70–79 7,621 156 12 7.7 7,559 261 45 17.2 41 (28–52) 66.8 (43.3–81.3) 55 (18–76) 55.4 (39.9–66.9) 
>80 1,263 37 7 18.9 1,332 47 12 25.5 18 (-29–48) — ¶ 26 (-69–68) — ¶ 
Total 19,254 315 27 8.6 19,247 642 80 12.5 51 (44–58) 66.5 (47.5–79.2) 39†† (7–59) 61.1 (51.1–69.1) 
*	 The analysis was performed on the Modified Intent-To-Treat (MITT) population that included all subjects randomized in the study who were followed for at least 30 days 
postvaccination and did not develop an evaluable case of herpes zoster (HZ) within the first 30 days postvaccination. 
† Age strata at randomization were aged 60–69 years and >70 years. 
§ Postherpetic neuralgia (PHN) was defined as HZ-associated pain rated as three or more, on a scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine), persisting 
or appearing more than 90 days after onset of HZ rash using Zoster Brief Pain Inventory. 
¶ VE for PHN and BOI calculated for the age groups 60–69 and >70 years. 
** Confidence interval. 
†† Age-adjusted estimate based on the age strata (age 60–69 years and >70 years) at randomization. 
Sources: Oxman MN, Levin MJ, Johnson GR, et al. Zoster Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 
2005;352:2271-84; ZOSTAVAX®. Package Insert. Merck & Co., Inc, Whitehouse Station, NJ 08889. 
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TABLE 3. Efficacy of zoster vaccine on the incidence of postherpetic neuralgia (PHN) among persons aged >60 years, by 
duration of pain* — Shingles Prevention Study 
Vaccine group Placebo group Efficacy¶ 
Persistence of No. confirmed Incidence No. confirmed Incidence 
PHN among 
all subjects† 
cases of HZ 
with PHN 
per 1,000 
person/yr§ 
cases of HZ 
with PHN 
per 1,000 
person/yr§ % (95% CI**) 
30 days 81 1.39 196 3.39 58.9 (46.6–68.7) 
60 days 45 0.77 113 1.96 60.4 (43.6–72.6) 
90 days 27 0.46 80 1.38 66.5 (47.5–79.2)†† 
120 days 17 0.29 54 0.93 68.7 (45.2–83.0) 
182 days 9 0.16 33 0.57 72.9 (42.1–88.6) 
* For the secondary end point, PHN was defined as the pain and discomfort associated with herpes zoster rated as three or more, 	on a scale ranging 
from 0 (no pain) to 10 (pain as bad as you can imagine), persisting or appearing more than 90 days after the onset of herpes zoster rash. Efficacy 
analyses were performed with the use of a follow-up interval that excluded the first 30 days after vaccination and the modified intention-to-treat 
population, which excluded persons who withdrew or in whom a confirmed case of herpes zoster developed, within the first 30 days after vaccination. 
Of the three persons who developed more than 1 confirmed case of herpes zoster, only the first case was included. 
† PHN was defined as the pain and discomfort associated with herpes zoster that was rated as three or more persisting or appearing more than 30, 60, 
90, 120, and 182 days after the onset of herpes zoster rash. 
§ For the total population and the subgroups stratified according to sex, the incidence of PHN in each treatment group (vaccine or placebo) was the 
weighted average of the observed incidence of PHN stratified according to age group, with weights proportional to the total number of person-years of 
follow-up in each age group. 
¶ Vaccine efficacy for the incidence of PHN and 95% confidence interval (CI). 
** Confidence interval. 
†† Vaccine efficacy for the incidence of PHN for all persons was the protocol-specified secondary end point. 
Source: Oxman MN, Levin MJ, Johnson GR, et al. Zoster Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older 
adults. N Engl J Med 2005;352:2271–84. 
Twelve clinical lots of zoster vaccine were used in the 
Shingles Prevention Study, nine of which were heat treated 
to accelerate aging of the vaccine. Potency upon shipment 
to study sites ranged from 21,000–62,000 PFUs/dose, but 
potency and accelerated aging did not significantly influ­
ence vaccine efficacy with regard to zoster, PHN, or BOI. 
Immunogencity 
A substudy of the Shingles Prevention Study was con­
ducted among 1,395 persons to assess VZV-specific 
immunity at baseline and 6 weeks following administra­
tion of zoster vaccine or placebo. The longer-term duration 
of immunogenicity also was assessed. Anamnestic antibody 
response was evaluated using gpELISA to measure increases 
in VZV antibody levels after vaccination. RCF and IFN-γ 
ELISPOT were used to measure the number of memory 
T-cells. With all three assays, VZV-specific immunity mea­
sured 6 weeks after vaccination increased following receipt 
of vaccine but not placebo. In both vaccine and placebo 
recipients, immune responses were inversely related to the 
risk for developing zoster; this association with protection 
was greatest for anamnestic antibody response following 
vaccination for which gpELISA Geometric Mean Titers 
(GMTs) increased 1.7-fold (95% CI = 1.6–1.8). However, 
for all three assays, no threshold level of immunity that 
predicted complete protection from zoster was observed. 
No clear dose response for increases in GMTs was 
observed; similar increases were achieved in vaccine 
recipients throughout the dosage range used in the Shingles 
Prevention Study (189). Peak CMI responses were present 
1–3 weeks following vaccination (187,190,191), as would 
be expected for anamnestic responses that would occur in 
persons with previous VZV infection. The impact of age 
on CMI response to vaccination also was evaluated. RCF 
and IFN-γ  ELISPOT responses were greater in persons aged 
60–69 years than in persons aged >70 years (p<0.01) (192). 
The increase in GMTs as a measure of anamnestic anti­
body response in persons aged 50–59 years was compa­
rable to that in persons aged >60 years (193). In a 
prelicensure study, subjects aged 55–70 years acquired 
VZV-specific class I-restricted and unrestricted cytotoxic­
ity following vaccination with even low levels (4,000 PFUs) 
of either live or heat-inactivated Oka/Merck strain of VZV 
(23). 
Duration of Efficacy and of Immunity 
Vaccine efficacy for zoster prevention declined during the 
first year following vaccination, but remained stable through 
the remaining 3 years of follow up (Figure 4). Vaccine effi­
cacy for PHN prevention had a similar pattern, with an 
initial decline and subsequent stabilization. After conclu­
sion of the Shingles Prevention Study, approximately 7,500 
vaccine recipients will be followed to extend observation to 
10 years. Because placebo recipients were offered zoster 
vaccine at the conclusion of the Shingles Prevention Study, 
zoster rates in these 7,500 persons will be compared with 
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FIGURE 4. Duration of zoster vaccine efficacy for preventing 
zoster and postherpetic neuralgia (PHN) 
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historic controls. Increases in RCF and IFN-γ  ELISPOT 
responses persisted for 3–6 years following vaccination 
(192,194). 
Safety and Adverse Events 
Serious Adverse Events 
Adverse events were monitored in the Shingles Prevention 
Study population, with more comprehensive ascertainment 
in a safety substudy comprising 6,616 persons (3,345 vac­
cine recipients and 3,271 placebo recipients) (Table 4). In 
the Shingles Prevention Study population, the number and 
types of serious adverse events (4) during the 42 days after 
receipt of vaccine or placebo were similar (1.4%). How­
ever, rates of serious adverse events in the safety substudy 
were higher in vaccine recipients (1.9%) than in placebo 
recipients (1.3%), with a relative risk of 1.5 (95% CI = 
1.0–2.3). Nonetheless, no temporal or clinical patterns of 
adverse events were observed in vaccine recipients to sug­
gest a causal relation (4,186). The incidence of death and 
hospitalizations was similar in the two treatment groups 
throughout the observation time (4,186). 
Mild Local and Systemic Reactions 
In the Shingles Prevention Study safety substudy, self-
reported injection site adverse events (e.g., erythema, pain, 
swelling, warmth, and pruritis) were more common among 
vaccine recipients (48.3%) than placebo recipients (16.6%) 
(p<0.05) (Table 4) (4); the risk for these events was higher 
in vaccine recipients aged 60–69 years (58.3%) than in 
persons aged >70 years (41.3%) (189). Most injection site 
adverse events were mild and resolved within 4 days (187). 
Less-serious systemic adverse events, including headaches, 
were more common in vaccine recipients (6.3%) than in 
placebo recipients (4.9%) (p<0.05) (Table 4) (4). The risk 
for fevers after vaccination did not differ between vaccine 
recipients and controls. 
The safety and tolerability of zoster vaccine was evalu­
ated in a separate study among persons aged 50–59 years, 
including 62 persons who received the standard potency 
(approximately 58,000 PFUs) and 123 persons who 
received high potency (approximately 207,000 PFUs) 
(195). Although the numbers of persons was small, both 
vaccines were safe and well tolerated; however, injection 
site reactions were more common (69.4% and 82.9%, 
respectively) than those observed in person aged >60 years 
in the Shingles Prevention Study (48.3%). 
Vaccine Virus Rash and Transmission 
Varicella-like rashes, including injection site varicella-like 
lesions, generalized varicella-like rashes, and zoster-like 
rashes, were evaluated in the Shingles Prevention Study 
during the first 42 days of observation (Table 4). Twenty 
vaccine recipients and seven placebo recipients had lesions 
at the injection site (p<0.05) (4); the lesions were tested 
for VZV by PCR in one of these persons in each group, 
and results were negative in both. Among the vaccine 
recipients, lesions occurred a median of 3–4 days after 
vaccination and lasted a median of 5 days. 
Generalized varicella-like rashes occurred at similar rates 
in the two groups (Table 4). Zoster-like rashes were less 
common in vaccine versus placebo recipients during this 
42-day period (p<0.05). Oka/Merck strain VZV was not 
detected in any of 10 lesion specimens from vaccine recipi­
ents available for PCR testing. In early studies conducted 
as part of the manufacturer’s clinical program for develop­
ment of zoster vaccine, samples from rashes in two vacci­
nated persons were confirmed to be Oka/Merck-strain VZV 
(186). Both experienced noninjection-site varicella-like 
rashes; one had 21 lesions on day 17 lasting 8 days and the 
other developed five lesions on day 8 that lasted 16 days. 
No varicella-like rashes were documented during any clini­
cal zoster vaccine trials of laboratory-confirmed zoster 
attributed to Oka/Merck strain VZV. In addition, no evi­
dence existed of transmission of vaccine virus from vaccine 
recipients to contacts. 
The Economic Burden of Zoster and 
Cost-Effectiveness of Vaccination 
The economic burden of zoster in the elderly is substan­
tial and includes direct costs attributed to health-care use 
and indirect costs attributed to losses in productivity from 
temporary or more permanent disability. In addition, 
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TABLE 4. Adverse events among all persons and among persons in an adverse-events substudy* 
Vaccine group Placebo group Difference in risk 
Event No. (%) No. (%) % (95% CI†) 
No. in group 19,270 19,276 
Day of vaccination to end of study 
Death 793 (4.1) 795 (4.1) 0.01 (-1.2–1.2)§ 
Death by age group (yrs) 
60–69 218 (2.1) 246 (2.4) -0.80 (-2.0–0.4)§ 
> 7 0 575 (6.5) 549 (6.2) 0.95 (-1.2–3.1)§ 
Vaccine-related serious adverse event¶ 2 (<0.1) 3 (<0.1) NC 
Day of vaccination to day 42 
Death 14 (0.1) 16 (0.1) -0.01 (-0.1–0.1) 
>1 serious adverse events 255 (1.4) 254 (1.4) 0.01 (-0.2–0.3) 
Varicella-like rash at injection site 20 (0.1) 7 (0.04) 0.07 (0.02–0.13)** 
Varicella-like rash not at injection site 18 (0.1) 14 (0.1) 0.02 (-0.04–0.09) 
Herpes zoster-like rash 17 (0.1) 36 (0.2) -0.10 (-0.18– -0.03)** 
Rash unrelated to herpes zoster 595 (3.2) 620 (3.3) -0.13 (-0.49–0.23) 
Confirmed case of herpes zoster 7 (<0.1) 24 (0.1) -0.09 (-0.16– -0.03)** 
Persons in the adverse event substudy 3345 3271 
Day of vaccination to end of study 
Person hospitalized 1,137 (34.0) 1,115 (34.1) 0.1 (-8.8–9.0)§ 
Hospitalization related to herpes zoster 5 (0.2) 6 (0.2) -0.1 (-0.7–0.5)§ 
Day of vaccination to day 42 
>1 serious adverse events 64 (1.9) 41 (1.3) 0.7 (0.1–1.3)** 
>1 adverse events 1,929 (58.1) 1,117 (34.3) 23.7 (21.3–26.0)** 
>1 systemic adverse events 820 (24.7) 768 (23.6) 1.0 (-1.0–3.1) 
>1 vaccine-related systemic adverse events¶ 209 (6.3) 160 (4.9) 1.4 (0.3–2.5)** 
Documented temperature >38.3oC (>100.9oF) 27 (0.8) 27 (0.9) 0 (-0.5–0.4) 
Self-reports of feeling abnormal temperature†† 231 (7.2) 190 (6.0) 1.2 (0.0–2.4) 
>1 adverse event at injection site§§ 1,604 (48.3) 539 (16.6) 31.7 (28.3–32.6)** 
Erythema 1,188 (35.8) 227 (7.0) 28.8 (26.9–30.6)** 
Pain or tenderness 1,147 (34.5) 278 (8.5) 26.0 (24.1–27.9)** 
Swelling 871 (26.2) 147 (4.5) 21.7 (20.1–23.4)** 
Pruritus 237 (7.1) 33 (1.0) 6.1 (5.2–7.1)** 
Warmth 57 (1.7) 11 (0.3) 1.4 (0.9–1.9)** 
Hematoma 53 (1.6) 46 (1.4) 0.2 (-0.4–0.8) 
R a s h 10 (0.3) 3 (0.1) 0.2 (0.0–0.5) 
* The rates of death and of hospitalization are percentages of persons in each treatment group. Otherwise, percentages are rates weighted in proportion 
to the number of persons with safety follow-up in each age group. NC denotes not calculated. Three persons who had withdrawn from the study because 
of worsening health and subsequently died were included in the safety analysis. 
† Confidence interval. 
§ The difference in risk (vaccine group versus placebo group) and the 95% confidence intervals (CIs) for deaths and hospitalizations are based on the 
rates per 1000 persons-years of follow-up to account for differential follow-up among the study participants as a result of staggered enrollment. 
Otherwise, the differences in risk and 95% CIs are based on an asymptotic method for the difference of two binomial proportions where the proportions 
are weighted according to the number of persons with safety follow-up in each age group. Negative values for the difference in risk result when the rate 
in the placebo group is larger than that in the vaccine group. 
¶ Events classified as possibly related to vaccination were assessed by a blinded investigator at each site. 
** P<0.05 for the comparison with the placebo group. 
†† A temperature of >38.3oC (>100.9oF) was not documented.
 
§§ None of the adverse events related to the injection site were considered to be serious adverse events.
 
Source: Oxman MN, Levin MJ, Johnson GR, et al. Zoster Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older
 
adults. N Engl J Med 2005;352:2271–4. 
much of the economic burden of zoster is borne by indi- emergency department visits, and 1–5 for the number of 
vidual patients as reduced quality of life because of pain medications prescribed. Approximately 1%–4% of zoster 
and suffering. Certain studies provide a range of estimates episodes result in hospitalization, with a mean duration of 
for health-care use among persons aged >60 years for treat- 4.8 days. (196–199). Health-care use for zoster and PHN 
ment of zoster and PHN. The estimates vary widely increases substantially with the age of patients (196–198). 
because of differing assumptions regarding the risk for PHN Costs associated with acute zoster have been evaluated. 
and of complications resulting from zoster. Estimated health- Among patients with acute episodes of zoster, average 
care use per case of zoster ranges from 1.3–3.1 for the num- expenditures ranged from $112–$287 per episode of out­
ber of outpatient visits, 0.005–0.12 for the number of patient care, $73–$180 per antiviral treatment, and 
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Goals and Objectives 
This report provides recommendations on use of the licensed live-attenuated vaccine for prevention of herpes zoster (zoster) and its most frequent complication, 
post-herpetic neuralgia (PHN). The recommendations were developed by CDC’s Advisory Committee on Immunization Practices. The goal of this report is to 
provide recommendations on the zoster vaccine for clinicians, public health officials, and others interested in preventing zoster and PHN in the United States. Upon 
completion of this educational activity, the reader should be able to 1) describe the epidemiology of zoster in the United States, 2) identify recommendations for 
zoster vaccination in the United States, and 3) and describe the characteristics of zoster vaccine. 
To receive continuing education credit, please answer all of the following questions. 
1.	 Which of the following statements about herpes zoster is true? 
A.	 It most frequently manifests in a sacral nerve dermatomal distribution. 
B.	 It most frequently manifests in a thoracic, cervical, or ophthalmic 
dermatomal distribution. 
C.	 It most frequently presents as a disseminated rash. 
2.	 The diagnosis of herpes zoster… 
A.	 Can usually be made on clinical grounds alone. 
B.	 Is made on the basis of testing antibody to varicella zoster virus. 
C.	 Neither A nor B. 
3.	 Which of the following statements is true regarding the epidemiology 
of herpes zoster? 
A.	 Approximately one in 10 persons acquire zoster during their lifetime. 
B.	 After adjusting for changes in age and other factors in the population, 
the rate for zoster in the United States has been stable in recent 
decades. 
C.	 Recent data suggest approximately 1 million cases of zoster occur 
annually in the United States. 
D.	 Exposure to varicella has been demonstrated to have major influence 
on the rate for zoster in the population. 
E.	 All of the above. 
4.	 Which of the following groups are at increased risk for herpes zoster? 
A.	 Persons at advanced age. 
B.	 Patients with atopic dermatitis. 
C.	 Blacks. 
D.	 Persons that have been vaccinated with varicella vaccine. 
E.	 All of the above. 
5.	 The most significant burden from zoster in the U.S. population is 
caused by… 
A.	 A high number of hospitalizations. 
B.	 A high number of deaths. 
C.	 Blindness caused by ophthalmic zoster. 
D.	 Impact on quality of life attributed to pain and suffering. 
6.	 Which of the following is true regarding zoster vaccine? 
A.	 It must be refrigerated before reconstitution. 
B.	 It is made from a different strain of varicella zoster virus than used in 
varicella vaccine. 
C.	 It should not be administered within 28 days of inactivated influenza 
vaccine. 
D.	 It contains thimerosol. 
E.	 None of the above. 
7.	 Which of the following is true regarding the efficacy of zoster vaccine 
in the Shingles Prevention Study? 
A.	 The vaccine reduced overall incidence of zoster by approximtaely 
51%. 
B.	 The vaccine was most effective at preventing the post-herpatic 
neuralgia (PHN) of the longest duration. 
C.	 The vaccine was not very effective at preventing zoster in persons aged 
>80 years but was much more effective at preventing PHN in these 
persons. 
D.	 Efficacy of the vaccine at preventing zoster was fairly stable over a 
period of 6 years. 
E.	 A, B, and C. 
8.	 The Advisory Committee for Immunization Practices (ACIP) 
recommends zoster vaccine for which of the following? 
A.	 Adults aged >50 years about to undergo kidney transplantation. 
B.	 Adults aged >60 years, with 1 booster dose 10 years later. 
C.	 Adults aged >60 years irrespective of prior history of varicella or zoster. 
D.	 Adults aged >60 who are experiencing zoster to prevent PHN. 
E.	 B, C, and D. 
9.	 Zoster vaccine is contraindicated by ACIP for which of the following 
persons? 
A.	 Persons with insulin-dependent diabetes mellitus. 
B.	 Persons infected with human immunodeficiency virus before 
progression to acquired immunodeficiency syndrome. 
C.	 Persons that received chemotherapy for leukemia during the 
preceding 3 months. 
D.	 A, B, and C. 
E.	 B and C. 
10. In the Shingles Prevention Study, which of the following adverse 
reactions occurred with significantly greater frequency in the zoster 
vaccine recipients as compared with controls? 
A.	 A generalized varicella-like rash. 
B.	 Injection site reactions. 
C.	 Fever. 
D.	 All of the above. 
11. What best describes your professional activities? 
A.	 Physician. 
B.	 Nurse. 
C.	 Health educator. 
D.	 Office staff. 
E.	 Other. 
12. I plan to use these recommendations as the basis for … (Indicate all 
that apply.) 
A.	 health education materials. 
B.	 insurance reimbursement policies. 
C.	 local practice guidelines. 
D.	 public policy. 
E.	 other. 
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13. Overall, the length of the journal report was … 
A.	 much too long. 
B.	 a little too long. 
C.	 just right. 
D.	 a little too short. 
E.	 much too short. 
14. After reading this report, I am confident I can describe the 
epidemiology of zoster in the United States. 
A.	 Strongly agree. 
B.	 Agree. 
C.	 Undecided. 
D.	 Disagree. 
E.	 Strongly disagree. 
15. After 	reading this report, I am confident I can identify 
recommendations for zoster vaccination in the United States. 
A.	 Strongly agree. 
B.	 Agree. 
C.	 Undecided. 
D.	 Disagree. 
E.	 Strongly disagree. 
16. After reading this report, I am confident I can describe the 
characteristics of zoster vaccine. 
A.	 Strongly agree. 
B.	 Agree. 
C.	 Undecided. 
D.	 Disagree. 
E.	 Strongly disagree. 
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17. The learning outcomes (objectives) were relevant to the goals of this 
report. 
A.	 Strongly agree. 
B.	 Agree. 
C.	 Undecided. 
D.	 Disagree. 
E.	 Strongly disagree. 
18. The instructional strategies used in this report (text, tables, and figures) 
helped me learn the material. 
A.	 Strongly agree. 
B.	 Agree. 
C.	 Undecided. 
D.	 Disagree. 
E.	 Strongly disagree. 
19. The content was appropriate given the stated objectives of the report. 
A.	 Strongly agree. 
B.	 Agree. 
C.	 Undecided. 
D.	 Disagree. 
E.	 Strongly disagree. 
20. The content expert(s) demonstrated expertise in the subject matter. 
A.	 Strongly agree. 
B.	 Agree. 
C.	 Undecided. 
D.	 Disagree. 
E.	 Strongly disagree. 
(Continued on pg CE-4) 
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21. Overall, the quality of the journal report was excellent. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
22. The recommendations will improve the quality of my practice. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
23. The availability of continuing education credit influenced my decision 
to read this report. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
24. The MMWR format was conductive to learning this content. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
25. Do you feel this course was commercially biased? (Indicate yes or no; if 
yes, please explain in the space provided below.) 
A. Yes. 
B. No. 
26. How did you learn about the continuing education activity? 
A. Internet. 
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal). 
C. Coworker/supervisor. 
D. Conference presentation. 
E. MMWR subscription. 
F. Other. 
Correct answers for questions 1–10. 
B; 2. A; 3. C; 4.A; 5. D; 6. E; 7. E; 8. C; 9. C; 10. B. 1.
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$3,221–$7,206 per hospitalization (2006 dollars). Addi­
tional costs associated with managing non-PHN complica­
tions (e.g., ocular, neurologic, and cutaneous) ranged from 
$1,158–$11,255 per complication, and from $566– 
$1,914 per episode of PHN. Among the subset of patients 
with PHN persisting from 30 days to 12 months, annual­
ized health-care costs, including costs of the acute episode, 
ranged from $2,159 to $5,387 (200,201). Although indi­
rect costs from death can occur with zoster, these costs 
result mostly from losses in work time caused by tempo­
rary or more permanent disability. Patients with zoster 
(including those progressing to PHN) lose an average of 
>129 hours of work per episode (197,198), including losses 
of 12 or more hours of work time and 69 hours of leisure 
time during the first 30 days (196). Data on the national 
economic impacts of zoster and its complications on 
quality of life have not been reported. 
Five studies have estimated the cost-effectiveness of a 
1-dose routine vaccination program of immunocompetent 
persons aged >60 years (196,197,199,202,203) (Table 5). 
One of these studies has not been published (196). All five 
studies used a Markov cohort model (105), followed a cost-
utility analytic approach that included a societal perspec­
tive (204,205), and used quality-adjusted life-year (QALY) 
scores to assess the incremental impact of the vaccine 
program on quality of life. Costs and health benefits were 
measured in 2005–2006 U.S. dollars, and a 3% discount 
rate was used to adjust health outcomes and costs. Model 
assumptions varied regarding duration of vaccine protec­
tion, the efficacy of the vaccine for preventing PHN among 
vaccine recipients who developed zoster, costs associated 
with vaccine adverse events, and costs attributed to losses 
in work productivity. None of the five models incorporated 
costs for losses in leisure time. Assuming a routine vaccina­
tion program with 100% coverage, the estimated QALYs 
gained ranged from 0.0016 (0.6 days) to 0.0087 (3 days). 
At a vaccine cost of $150 per dose, the societal costs of 
routinely vaccinating immunocompetent persons aged >60 
years range from $27,000 to $112,000 per QALY gained. 
In the sensitivity analyses, variables with the strongest 
influence on outcomes include vaccine costs, duration of 
vaccine efficacy, risks for PHN as a complication, and costs 
and QALY scores for zoster and its complications. 
Although costs per QALY gained are most appropriately 
used to prioritize among competing programs for purposes 
of resource allocation, policymakers often decide whether 
or not to support programs by comparing their cost per 
QALY against a standard threshold. A threshold suggested 
by the World Health Organization is three times the gross 
domestic product per capita, which would be $94,431 for 
the United States (206). Alternatively, policymakers often 
decide about supporting programs by comparing their cost 
per QALY with the values for other widely accepted inter­
ventions. Compilations of such cost effectiveness data have 
been published and maintained in on-line registries 
(207,208). The estimated cost per QALY for zoster vacci­
nation covers a wide range that appears acceptable in com­
parison to either standard thresholds or to other established 
interventions, but it is at the intermediate-to-high end of 
that range. 
Summary of Rationale for Zoster 
Vaccine Recommendations 
The availability of a safe and effective vaccine for zoster 
offers an opportunity to decrease the burden of this disease 
and its complications among persons with high levels of 
risk. In the United States, the vaccine is licensed for use 
among persons aged >60 years, and routine vaccination of 
this population is recommended for several reasons. First, 
zoster causes substantial morbidity in the United States, 
with approximately 1,000,000 new cases occurring annu­
ally (62). Many of these cases cause debilitating pain, and 
when PHN develops, the pain can last for months or even 
years. Other complications include involvement of the eye 
that can threaten sight, bacterial superinfections, and dis­
figuring facial scarring. Second, although effective antiviral 
medications for treatment of zoster are available, adminis­
tration must be initiated within 72 hours of rash onset for 
maximum benefit. Many patients might not obtain such 
rapid diagnosis and treatment, and even when they do, the 
treatment is only partially effective at alleviating the symp­
toms and shortening their duration. Third, available treat­
ments for PHN often do not completely alleviate the pain 
and might be poorly tolerated by the older patients (31,33). 
Finally, available evidence suggests the cost-effectiveness of 
zoster vaccine is within the range of some other public 
health interventions. 
In a large, placebo-controlled clinical trial, the zoster vac­
cine reduced BOI attributed to zoster by 61.1 % and the 
incidence of PHN by 66.5 %. The vaccine reduced the 
overall incidence of zoster by 51.3 % and substantially 
reduced its associated pain (4). Although the vaccine was 
more efficacious in persons aged 60–69 years, substantial 
efficacy against zoster was observed in persons aged 
>70 years, and PHN was prevented in older age groups. 
Prevention of zoster and its sequelae is particularly impor­
tant among the oldest persons because they experience the 
highest incidence of zoster and PHN, they might be least 
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TABLE 5. Economic burden and projected cost-effectiveness of a herpes zoster vaccination program, by selected studies* — 
United States 
Study No. 1† Study No. 2 Study No. 3 Study No. 4 Study No. 5§ 
Costs 
Acute zoster 
Outpatient care $246–$312¶ $214 (SD** = $52.7) $287 ($221–$422) $112 ($56–$224) $289 ($178–$527) 
Antiviral medicines $73–$135 $155 NA†† $180 ($135–$238) NA 
Hospitalization $6,815 (SD = $11,608) $8,521 $7,206 ($6,529–$8,401) $6,884 $3,221 ($130–$5,200) 
Out-of-pocket§§ $7–$20 NA NA NA  N/A 
Complications (nonpostherpetic 
neuralgia [PHN])¶¶
 
Ocular $1,158 (SD = $2,231) $1,827 (SD= $2,844) $11,255 ($9,255–$13,255) NA NA
 
Neurologic $1,642 (SD = $3,483) $2,623 (SD= $3,965) NA NA NA
 
Cutaneous $1,851 (SD = $1,838) $3,739 (SD= $5,684) NA NA NA
 
PHN***
 
Outpatient care and prescriptions $903–$1071 $1,914 (SD= $2,667) $566 ($483–$673) $996 NA
 
Out-of-pocket $29–$118 NA NA NA NA
 
Productivity losses per case††† $1,062 $2,437 $782 (0–$1,000) $744 ($185–$1,934) NA 
Cost-Effectiveness 
Outcomes prevented per million person-years
 
Zoster 58,000 66,000 NA NA NA
 
Complications (non-PHN) 7,000 8,500 NA NA NA
 
PHN 32,000 20,000 NA NA NA
 
Premature deaths 5 37 NA NA NA
 
Resource-use averted per million person-years
 
Outpatient visits 285,000 274,000 NA NA NA
 
Emergency department visits 28,000 8,700 NA NA NA
 
Hospitalization days 6,000 8,900 NA NA NA
 
Prescription fills 176,000 354,000 NA NA NA
 
QALYs gained per person-year§§§ 0.0087 0.0057 0.0021 0.0016 NA 
Vaccine cost per dose¶¶¶ $150 ($50–$200) $150 $145 ($50–$150) $200 ($50–$500) $170 ($123–$245) 
Cost per QALY****,§§§ $55,000 $27,000 $112,000 $100,000 $50,000 
*	 Study No. 1: Ortega-Sanchez IR. Projected cost-effectiveness of vaccinating US elderly to prevent shingles. Oral presentation to the Advisory Committee for Immunization 
Practices (ACIP) Meeting, June 2006; Study No. 2: Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness In the United States of a vaccine to prevent herpes 
zoster and postherpetic neuralgia in older adults. Vaccine 2007;25:8326–37; Study No. 3: Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent 
herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007;44:1280–8; Study No. 4: Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent 
herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006;145:317–25; Study No. 5: Ho A, Coplan PM, Lee A, et al. Cost-effectiveness of vaccination against 
herpes zoster in the elderly population. Canadian J Anesthesia (Suppl 1): 26394. Studies used a Markov cohort model. Except for Study 5, which considered vaccinating 
immunocompetent persons aged >65 years, studies No. 1–4 evaluated a routine vaccination program of immunocompentent persons aged >60 years. Baseline for comparison 
in all studies was “no vaccination.” Study No. 5 measured medical costs of zoster in 2002 U.S. dollars and Studies No. 1–4 measured age-specific costs in 2005–2006 U.S. dollars. 
†	 For rates of zoster incidence and medical costs, Study No. 1 used data mainly from MedStat. For rates of zoster incidence and complications, the study used:Yawn BP, Saddier 
S, Wollan P, Sauver JS, Kurland M, Sy L. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin 
Proc 2007;82:1341–9. For quality-of-life scores with zoster, out-of-pocket, and productivity costs, the study used: Lieu TA, Ortega-Sanchez IR, Ray GT, et al. Community and 
patient values for preventing zoster. Pharmacoeconomics 2008;26:235–49. 
§ For incidence of zoster, Study No. 5 used data mainly from: Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older 
adults. N Engl J Med 2005;352:2271–84; CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 
2007;56(No. RR-4). Medical costs from 1995 were updated to 2002 U.S. dollars. 
¶ Ranges in medical costs described age-specific costs for zoster or PHN cases among persons aged >60 years. High and low medical costs also were used for sensitivity analysis. 
** SD = Standard deviation. In addition to reported mean costs, SD values were used for sensitivity analysis. 
†† NA = not available.
 
§§
 Out-of-pocket costs are monetary expenses associated with zoster or PHN as reported by patients and include medical and nonmedical payments, over-the-counter medications, 
travel expenses, and other monetary expenses. 
¶¶ Study Nos. 1–3 included costs of frequent non-PHN complications observed <30 days after zoster reactivation (i.e., ocular, neurologic, and cutaneous complications). 
***	 Study Nos. 1 and 2 used costs attributable to PHN cases lasting >90 days, and study No. 4 used cost attributable to PHN cases lasting 182 days ($166 per month). Although 
Study No. 3 assumed that 43%–56% of PHN cases lasted >12 months, attributable costs were not explicitly defined. 
†††	 Productivity losses (i.e., indirect costs) in cases of zoster and PHN were related to monetary value of time of work missed or income lost. Losses from leisure time or unpaid 
activities were not included. Although zoster can cause death, no productivity costs associated with premature deaths were included. 
§§§ Source of quality-of-life values to estimate quality-adjusted live years (QALYs) differed across studies. Source of quality-of-life values to estimate quality-adjusted life years 
(QALYs) differed across studies. For all five studies, quality-of-life values are based on published data with valuation by representative samples of community members. In 
addition, study No. 1 also used published quality-of-life values using valuation by zoster patients, yielding values of QALYs gained per person-year of 0.019 and cost per QALY 
of $23,000. 
¶¶¶ Range in vaccine costs were used for sensitivity analyses. Study No. 4 reported an aggregated cost for the vaccine and vaccine administration equal to $200. Except for Study 
No. 5, vaccine administration costs also were included (i.e., $3.50 in Study No. 3, $18 in Study No. 2, and $15–$30 in Study No. 1). 
**** Estimates of cost per QALY saved assumed that PHN cases were avoided only through the prevention of zoster cases.When PHN cases were prevented in persons with zoster 
for whom the vaccine failed to prevent zoster (i.e., burden of illness), a societal cost of $35,000 per QALY saved was estimated by Study No. 1. 
able to seek medical attention for zoster and PHN and to to treat PHN, they might have the least reserve to tolerate 
request treatment of ongoing pain, they might be least able zoster and its complications, and they are most likely to 
to tolerate the medications and procedures commonly used suffer social and psychological consequences from PHN. 
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Recommendations for Use of
 
Zoster Vaccine
 
Routine Vaccination of Persons Aged 
>60 Years 
ACIP recommends routine vaccination of all persons aged 
>60 years with 1 dose of zoster vaccine. Persons who report 
a previous episode of zoster and persons with chronic medical 
conditions (e.g., chronic renal failure, diabetes mellitus, 
rheumatoid arthritis, and chronic pulmonary disease) can 
be vaccinated unless those conditions are contraindications 
or precautions. Zoster vaccination is not indicated to treat 
acute zoster, to prevent persons with acute zoster from 
developing PHN, or to treat ongoing PHN. Before routine 
administration of zoster vaccine, it is not necessary to ask 
patients about their history of varicella (chickenpox) or to 
conduct serologic testing for varicella immunity. 
Simultaneous Administration with Other 
Adult Vaccines 
Immunogenicity of zoster vaccine and trivalent inacti­
vated influenza vaccine is not compromised when the two 
vaccines are administered simultaneously (186). However, 
no data exist on administration of zoster vaccine with other 
vaccines routinely recommended for persons aged >60 years, 
which are all inactivated. In general, the simultaneous 
administration of most widely used live, attenuated and 
inactivated vaccines has not resulted in impaired immune 
response or an increased rate of adverse events (209). There­
fore, zoster vaccine can be administered with other 
indicated vaccines during the same visit (e.g., Td, Tdap, 
and pneumococcal polysaccharide vaccines). Each vaccine 
must be administered using a separate syringe at a differ­
ent anatomic site. If simultaneous administration is not 
possible, zoster vaccine can be administered at any time 
before or after an inactivated vaccine, but at least 4 weeks 
before or after another live, attenuated vaccine (209). 
Groups for Which Vaccine is Not 
Licensed 
Vaccination of Persons Aged <60 Years 
The vaccine is not licensed for persons aged <60 years, 
and no recommendation exists for routine vaccination of 
persons aged <60 years. In the clinical trial, the zoster vac­
cine was evaluated among persons aged >60 years. The vac­
cine was most effective and well tolerated in the youngest 
persons (Table 1) (4). Although the vaccine would 
probably be safe and effective in persons aged <60 years, 
data are insufficient to recommend vaccination of these 
persons at this time. 
Vaccination of Persons Who Have Received 
Varicella Vaccine 
Zoster vaccination is not recommended for persons of 
any age who have received varicella vaccine. However, health-
care providers do not need to inquire about varicella vacci­
nation history before administering zoster vaccine because 
virtually all persons currently or soon to be in the recom­
mended age group have not received varicella vaccine. In 
the United States, varicella vaccination began in 1995. Since 
that time, few adults aged >40 years would have been sus­
ceptible to varicella and thus eligible to receive varicella 
vaccine (5). The number of persons eligible for zoster vac­
cination who have received varicella vaccine is extremely 
small and will remain so for at least a decade. 
Special Groups and Circumstances 
Persons with a Reported History of Zoster 
Persons with a reported history of zoster can be vacci­
nated. Repeated zoster has been confirmed in immuno­
competent persons soon after a previous episode (4). 
Although the precise risk for and severity of zoster as a func­
tion of time following an earlier episode are unknown, some 
studies suggest it may be comparable to the risk in persons 
without a history of zoster (62,169). Furthermore, no labo­
ratory evaluations exist to test for the previous occurrence 
of zoster, and any reported diagnosis or history might be 
erroneous (4,64,65). Although the safety and efficacy of 
zoster vaccine have not been assessed in persons with a his­
tory of zoster, different safety concerns are not expected in 
this group. 
Persons Anticipating Immunosuppression 
The risk for zoster and its severe morbidity and mortal­
ity is much greater among persons who are immunosup­
pressed. Review of vaccination status for zoster and other 
vaccines should be a key component of the medical assess­
ment for immunocompetent patients aged >60 years who 
might be anticipating initiation of immunosuppressive treat­
ments or who have diseases that might lead to immunode­
ficiency. Such patients without a history of zoster vaccination 
should receive 1 dose of zoster vaccine at the first possible 
clinical encounter while their immunity is intact. Zoster 
vaccine should be administered at least 14 days before ini­
tiation of immunosuppressive therapy, although some 
 20 MMWR June 6, 2008 
experts advise waiting 1 month after zoster vaccination to 
begin immunosuppressive therapy if delay is possible (210). 
Persons Receiving Antiviral Medications 
Licensed antiviral medications active against members of 
the herpesvirus family include acyclovir, famciclovir, and 
valacyclovir. These agents might interfere with replication 
of the live, VZV-based zoster vaccine. All three agents have 
relatively short serum half-lives and are quickly cleared from 
the body. Persons taking chronic acyclovir, famciclovir, or 
valacyclovir should discontinue these medications at least 
24 hours before administration of zoster vaccine, if pos­
sible (209). These medications should not be used for at 
least 14 days after vaccination, by which time the immu­
nologic effect should be established (209). 
Persons Receiving Blood Products 
Zoster vaccine can be administered to persons at any time 
before, concurrent with, or after receiving blood or other 
antibody-containing blood product because persons with 
a history of varicella indefinitely maintain high levels of 
antibody to VZV, and the levels are comparable to those 
found in donated blood and antibody-containing blood 
products (e.g., whole blood, packed red blood cells, and 
plasma immune globulin, hyperimmune globulin, and 
intravenous immune globulin) (192,211). 
Nursing Mothers 
Most live vaccines, including varicella vaccine, are not 
secreted in breast milk (209,212). Therefore, breast feed­
ing is not a contraindication for zoster vaccination. However, 
this situation will be extremely rare in the target age group 
for this vaccine. 
Contraindications 
Allergy to Vaccine Components 
Zoster vaccine is contraindicated for persons who have a 
history of anaphylactic reaction to any component of the 
vaccine, including gelatin and neomycin. Neomycin allergy 
is usually manifested as a contact dermatitis, which repre­
sents a delayed-type immune response. A history of con­
tact dermatitis to neomycin is not a contraindication for 
receiving zoster vaccine (209). 
Immunocompromised Persons 
Zoster vaccine should not be administered to persons with 
primary or acquired immunodeficiency including: 
• Persons with leukemia, lymphomas, or other malignant 
neoplasms affecting the bone marrow or lymphatic 
system. However, patients whose leukemia is in remis­
sion and who have not received chemotherapy (e.g., 
alkylating drugs or antimetabolites) or radiation for at 
least 3 months can receive zoster vaccine (209). 
• Persons with AIDS or other clinical manifestations of 
HIV, including persons with CD4+ T-lymphocyte val­
ues <200 per mm3 or <15% of total lymphocytes. 
• Persons on immunosuppressive therapy, including 
high-dose corticosteroids (>20 mg/day of prednisone 
or equivalent) lasting two or more weeks. Zoster vacci­
nation should be deferred for at least 1 month after 
discontinuation of such therapy (209). Short-term cor­
ticosteroid therapy (<14 days); low-to-moderate dose 
(<20 mg/day of prednisone or equivalent); topical (e.g., 
nasal, skin, inhaled); intra-articular, bursal, or tendon 
injections; or long-term alternate-day treatment with 
low to moderate doses of short-acting systemic corti­
costeroids are not considered to be sufficiently immu­
nosuppressive to cause concerns for vaccine safety. 
Persons receiving this dose or schedule can receive zoster 
vaccine. Therapy with low-doses of methotrexate (<0.4 
mg/Kg/week), azathioprine (<3.0 mg/Kg/day), or 6­
mercaptopurine (<1.5 mg/Kg/day) for treatment of 
rheumatoid arthritis, psoriasis, polymyositis, sarcoido­
sis, inflammatory bowel disease, and other conditions 
are also not considered sufficiently immunosuppres­
sive to create vaccine safety concerns and are not 
contraindications for administration of zoster vaccine. 
• Persons with clinical or laboratory evidence of other 
unspecified cellular immunodeficiency. However, per­
sons with impaired humoral immunity (e.g., 
hypogammaglobulinemia or dysgammaglobulinemia) 
can receive zoster vaccine. 
• Persons undergoing hematopoietic stem cell transplan­
tation (HSCT). The experience of HSCT recipients with 
VZV-containing vaccines (e.g., zoster vaccine) is lim­
ited. Physicians should assess the immune status of 
the recipient on a case-by-case basis to determine the 
relevant risks. If a decision is made to vaccinate with 
zoster vaccine, the vaccine should be administered at 
least 24 months after transplantation (209). 
• Persons receiving recombinant human immune media­
tors and immune modulators, especially the antitumor 
necrosis factor agents adalimumab, infliximab, and 
etanercept. The safety and efficacy of zoster vaccine 
administered concurrently with these agents is 
unknown. If it is not possible to administer zoster vac­
cine to patients before initiation of therapy, physicians 
should assess the immune status of the recipient on a 
case-by-case basis to determine the relevant risks and 
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benefits. Otherwise, vaccination with zoster vaccine 
should be deferred for at least 1 month after discon­
tinuation of such therapy. 
Pregnancy 
Zoster vaccine is not recommended for use in pregnant 
women, although these women are unlikely to be in the 
vaccine target age group. The effects of the live, attenuated 
VZV-based zoster vaccine on the fetus are unknown. 
Women should avoid becoming pregnant for 4 weeks fol­
lowing zoster vaccination. Having a pregnant household 
member is not a contraindication to zoster vaccination. If a 
pregnant woman is vaccinated or becomes pregnant within 
1 month of vaccination, she should be counseled about 
potential effects on the fetus. Wild-type VZV poses a small 
risk to the fetus (3), and the fetal risk from the attenuated 
zoster vaccine is probably even lower. Furthermore, virtu­
ally all persons receiving the vaccine will have preexisting 
VZV immunity, which is expected to limit viral replica­
tion and presumably further reduce fetal risk. In most cir­
cumstances, the decision to terminate a pregnancy should 
not be based on whether zoster vaccine was administered 
during pregnancy. Merck & Co., Inc., in collaboration with 
CDC, has established a pregnancy registry to monitor the 
maternal-fetal outcomes of pregnant women who are inad­
vertently administered live-attenuated VZV-based vaccines 
within 1 month of pregnancy (telephone: 800-986-8999). 
Patients and health-care providers should report any expo­
sure to zoster vaccine during pregnancy to this registry. 
Precautions 
Moderate to Severe Illness 
Zoster vaccination of persons who have severe acute ill­
ness should be postponed until recovery. The decision to 
delay vaccination depends on the severity of symptoms and 
the etiology of the disease. Zoster vaccine can be adminis­
tered to persons who have mild acute illnesses with or 
without fever (209). 
Program Implementation Issues 
Following Good Adult Vaccination Practices 
Zoster vaccine should be offered to patients aged >60 
years at the first available clinical encounter with their pro­
vider. The average adult in this age group has 5–8 clinical 
encounters with their provider annually (213). Strategies 
to promote zoster vaccination include linking delivery of 
zoster vaccine to delivery of other indicated adult vaccines 
(e.g., influenza) and preventive-health interventions (214– 
217), standing orders so that patients will automatically 
be offered indicated vaccines rather than requiring case-
by-case physicians’ orders (218), and practice-based audits 
and/or physician-reminder systems (218). Residents of 
nursing homes and other long-term–care facilities who are 
at least aged 60 years and without contraindications should 
be included in routine zoster vaccination activities. When 
administering zoster vaccine, health-care providers should 
review the patient’s vaccination status for all indicated adult 
vaccines (219,220). 
ACIP recommends that health-care providers keep per­
manent documentation of all administered vaccines, includ­
ing zoster vaccine, in the vaccine recipient’s permanent 
medical record (209). The type of the vaccine, manufac­
turer, anatomic site, route of delivery, date of administra­
tion, lot number, and name of the administering facility 
should be recorded. To help avoid the administration of 
unnecessary doses, every patient should be given a record 
of the vaccination. 
Administration Errors 
The zoster vaccine, ZOSTAVAX®, is a live, attenuated 
vaccine containing Oka/Merck strain VZV. The vaccine is 
similar to the varicella vaccine, VARIVAX®, except the mini­
mum PFU-content of the ZOSTAVAX® is at least 14-fold 
higher than the minimum PFU-content of VARIVAX®. 
Opportunities for administration errors are possible. 
For providers who serve both children and adults, physi­
cal separation of products, careful visual inspection and 
reading of labels, and preparation of vaccine for patient use 
only at time of vaccination can help prevent errors. If a 
provider mistakenly administers high-potency zoster vac­
cine to a child indicated for varicella vaccine, the level of 
protection against varicella would probably be at least the 
same as for conventional doses of varicella vaccine. This 
erroneous dose should count as a single valid dose of vari­
cella vaccine. If the erroneous dose was administered in lieu 
of the first dose of varicella vaccine, a second dose of vari­
cella vaccine is required. Administration errors involving 
zoster vaccine should be reported to VAERS whether or 
not an adverse event occurs. 
Early clinical trials for prevention of varicella were con­
ducted in susceptible children using a formulation of live-
attenuated Oka/Merck strain VZV at doses of 17,430 PFU, 
approaching the range of PFU in zoster vaccine (>19,400 
PFU). This high-dose formulation was well tolerated and 
efficacious (221). The more recently licensed live, attenu­
ated Oka-strain VZV vaccine (PROQUAD®) prepared in 
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combination with measles, mumps, and rubella vaccine 
(MMRV) is formulated with a broad range of titers that 
extend to over 60,000 PFU (222,223). 
Varicella vaccine (VARIVAX®) is not indicated for pre­
vention of zoster. MMRV vaccine (PROQUAD®) is not 
licensed for use in persons aged >13 years. If a provider 
mistakenly administers varicella vaccine to persons indi­
cated for zoster vaccine, no specific safety concerns exists, 
but the dose should not be considered valid and the 
patient should be administered a dose of zoster vaccine dur­
ing that same visit. If the error is not immediately detected, 
a dose of zoster vaccine should be administered as soon as 
possible but not within 28 days of the varicella vaccine 
dose to prevent potential interference of 2 doses of live 
attenuated virus. 
Risk for Transmission of Oka/Merck Strain 
after Receiving Zoster Vaccine 
Persons having close household or occupational contact 
with persons at risk for severe varicella need not take any 
precautions after receiving zoster vaccine except in rare 
instances in which a varicella-like rash develops, when stan­
dard contact precautions are adequate. Although transmis­
sion of Oka/Merck strain VZV has been documented 
following varicella vaccination, such transmission is rare and 
has only been documented when the vaccine recipient first 
developed a varicella-like rash. Rates of varicella-like rash 
appear to be less common following zoster vaccination than 
following varicella vaccination (4), and transmission of the 
Oka/Merck strain VZV from recipients of zoster vaccine 
has not been detected. The risk for transmitting the 
attenuated vaccine virus to susceptible persons should be 
weighed against the risk for developing wild-type zoster 
that could be transmitted to a susceptible person. If a sus­
ceptible, immunocompromised person is inadvertently 
exposed to a person who has a vaccine-related rash, 
VARIZIG™ need not be administered because disease as­
sociated with this type of transmission is expected to be 
mild. Acyclovir, valacyclovir, and famciclovir are active 
against live-attenuated Oka/Merck strain VZV and can be 
used in the unlikely situations in which a severe illness 
develops in the susceptible contact. 
Reporting of Adverse Events after 
Vaccination 
As with any newly licensed vaccine, surveillance for rare 
adverse events associated with administration of zoster vac­
cine is important for assessing its safety in widespread use. 
Vaccine safety surveillance in the age group for which zoster 
vaccine is recommended (aged >60 years) will present chal­
lenges because of the high prevalence of chronic conditions, 
the frequent use of multiple medications, and the common 
occurrence of medical events. Coincident adverse events can 
be anticipated following zoster vaccination, but many of 
these could be caused by the vaccine as well. All clinically 
significant adverse events should be reported to VAERS even 
if causal relation to vaccination is not certain. VAERS 
reporting forms and information are available electronically 
at http://www.vaers.hhs.gov or by telephone (800-822­
7967). Web-based reporting is also available, and provid­
ers are encouraged to report electronically at https:// 
secure.vaers.org/VaersDataEntryintro.htm. 
Future Research and Directions 
Key questions remain regarding optimal implementation 
of zoster vaccination and preventing zoster and its compli­
cations. Areas that need particular focus include: 
• Surveillance for zoster and its complications. Zoster is 
not a notifiable condition. Other strategies will be 
needed to monitor zoster and its complications include 
using administrative databases, population-based sur­
veys, or active surveillance in sentinel sites. Because the 
primary disease burden associated with zoster is pain, 
capturing this condition will be particularly challeng­
ing using any surveillance strategy. 
• Durability of protection against zoster and its compli­
cations afforded by the zoster vaccine. In a persistence 
substudy ongoing at 12 of 22 of the original zoster 
vaccine study sites, follow up of vaccine recipients will 
be extended to an observation time of 10 years. How­
ever, no concurrent randomized placebo group exists 
to which these vaccine recipients can be compared, and 
results will be compared against historic controls. Large 
administrative databases also will be important in evalu­
ating changes in vaccine effectiveness over time. These 
and other available data will help to determine changes 
in vaccine policy (e.g. a booster dose). However, both 
of these approaches might be confounded by secular 
changes in the incidence of zoster. 
• Increased understanding of the epidemiology of zoster. 
Better knowledge of age-adjusted changes in the inci­
dence of zoster and risk factors for any such changes 
will help determine the long-term effectiveness of the 
zoster vaccine and clarify whether changes in VZV cir­
culation caused by varicella vaccination might be 
affecting zoster incidence. A better understanding of 
the epidemiology and risk factors for zoster might also 
lead to changes in policy regarding use of zoster vac­
cine (e.g., targeting the vaccine to selected risk groups 
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that are not now covered by the vaccine recommenda­
tions or lowering the targeted age group). Additional 
information is needed to define risks for zoster in vari­
cella-vaccinated adults attributed to Oka/Merck strain 
VZV from the vaccine itself or to wild-type VZV from 
breakthrough varicella. Although studies involving both 
immunocompromised and immunocompetent children 
provided evidence that the risks for zoster are lower in 
varicella-vaccinated children than in children with natu­
rally acquired varicella (3,99,100,224), characteriza­
tion of these risks in older adults will involve longer 
follow up. 
• Better prevention and treatment strategies for zoster 
and PHN. Although licensure of zoster vaccine repre­
sents an important milestone in prevention of zoster, 
the vaccine remains only partially efficacious and is not 
licensed for all populations and age groups at risk. 
Although available treatments for zoster and PHN have 
improved, treatment of these conditions remains inad­
equate. Improved prevention and treatment strategies, 
including better vaccines, are needed to reduce the dis­
ease burden of zoster. ZOSTAVAX® or other active or 
inactive formulations of zoster vaccine should be evalu­
ated in additional cohorts of persons (e.g., persons aged 
50–59 years and immunosuppressed persons at the 
highest risk for zoster and its complications). Patients 
infected with HIV, with or without AIDS, could 
benefit substantially from the prevention of zoster. A 
better understanding of immunologic correlates of pro­
tection against zoster would help facilitate the devel­
opment and evaluation of such new zoster prevention 
strategies. 
• The epidemiology of zoster in persons with a history of 
varicella vaccination. Available data suggest that chil­
dren vaccinated with varicella vaccines are at reduced 
risk for Oka/Merck strain zoster as compared with the 
risk for zoster from wild-type VZV in children with a 
history of chickenpox. However, this evidence does not 
extend to vaccine recipients as they become older. Nor 
does it include decades of time after vaccination, par­
ticularly in the absence of circulating VZV that could 
externally boost immunity. Data also are lacking 
regarding the risk for zoster from wild-type VZV in 
vaccinated persons with a history of breakthrough vari­
cella. These issues should be addressed in future stud­
ies to develop zoster vaccination policy for cohorts of 
vaccine recipients as they age. 
• Safety of zoster vaccination. Postlicensure studies to 
evaluate further the safety of the zoster vaccine are 
under development and will be conducted by the manu­
facturer.  Clinical trials have been completed to assess 
the safety and immunogenicity of simultaneous admin­
istration of zoster vaccine and formulations of influ­
enza vaccine. In addition, independent studies are being 
developed by CDC to monitor safety through VAERS 
and the CDC Vaccine Safety Datalink. 
Additional Information About 
Zoster and Zoster Vaccine 
Additional information about zoster and zoster vaccine 
is available from several sources, and new information will 
be available in the future. Updated information about 
zoster, PHN, and zoster vaccine is available at http:// 
www.cdc.gov/vaccines/vpd-vac/shingles/default.htm. 
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